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CHAPTER 1.1 
Burden of Depression 
The term “depression” originated from the French word “depressare”, which is related 
to “deprimere”, meaning “to press down” (1). However, the concept of depression was 
known to ancient Greeks as melancholia which was defined by the symptoms “repulsion 
to eat, despondency, insomnia, irritability and restlessness” (2, 3). Only in the 20th 
century has depression received a precise definition. Thus according to the Diagnostic 
and Statistical Manual of Disease (DSM) 4th Edition, a major depressive episode occurs 
when patients exhibit 5 or more of the following symptoms that persist for at least 2 
weeks: depressed mood, diminished interest or pleasure in all activities, significant 
weight loss or weight gain, insomnia or hypersomnia, psychomotor retardation or 
agitation, fatigue, feeling of worthlessness or guilt, diminished ability to concentrate and 
recurrent thoughts of suicide or death (4). 
 Depression is one of the commonest psychiatric disorders accounting, in Europe, 
for approximately 13% life-time incidence with 4% being diagnosed with major depres-
sion in the previous 12 months (5). Depression has a major detrimental impact on the 
quality of life of the patient irrespective of the geographical, educational, socioeco-
nomic and racial boundaries. According to the 1990 Global Burden of Disease of the 
World Health Organisation (WHO) (6), depression has a greater negative impact on the 
quality of life of the patient than cardiovascular disease and has been projected to be the 
second most important cause of disability, as disability adjusted years, by 2030 (7). This 
finding has been replicated in several national studies (8-10). In addition, mood disor-
ders and anxiety disorders rank more highly than a number of common physical disor-
ders in terms of the number of days lost from work (11). Disability in key occupational, 
domestic and social roles is strongly related to both the severity and persistence of the 
disorder (12). 
 The pattern of occurrence, increasing severity and the frequency of resistance to 
treatment are some of the reasons for the high burden of depression (13, 14). Depression 
is frequently a recurrent condition and whereas the outcome of acute treatment is 
generally good, a small proportion of patients show poor treatment response with up to 
30% showing only a partial response. It has been estimated that about 30% of patients 
relapse in the first year of treatment while about 80% of those with major depression 
have at least one further episode (15). These facts emphasise the importance of timely 
and adequate treatment in preventing the disorder from becoming a chronic condition. 
Unfortunately antidepressants are frequently limited in their efficacy and have unac-
ceptable side effects combined with a slow onset of action with frequent interactions 
with concurrent medication. This leads to poor patient compliance that has been esti-
mated to be about 56% following the first 3 months of antidepressant treatment (16), the 
placebo response being as high as 30%. Thus there is a need to develop more effective 
and better tolerated antidepressants. Diagnostic and prognostic markers of depression 
would undoubtedly assist not only in the accurate and early diagnosis of the disorder but 
also help to predict the possible outcome of antidepressant treatment. 
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How do antidepressants work: a synopsis of the monoamine 
hypothesis of depression 
Monoamine Hypothesis 
There are many theories and hypotheses regarding the pathophysiology of depression. 
However, for most of the last 50 years, the biological approach to depression has been 
dominated by the monoamine hypothesis (17). This hypothesis proposes that depression 
is caused by a functional deficit in monoamines, particularly noradrenalin and serotonin, 
at key sites in the brain. The hypothesis was also developed to explain the antidepres-
sant effects of the tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors 
(MAOIs) (18, 19). 
 However, the hypothesis could neither explain why up to 2-3 weeks of continued 
medication was needed to alleviate depressive symptoms, even though monoamine 
changes often occur within 1-2 days nor why other drugs such as cocaine and ampheta-
mine that enhanced serotonergic or noradrenergic transmission are not effective in 
treating depression (20). Furthermore, the hypothesis could not explain why antidepres-
sants are effective in other disorders, such as social phobia (21), why other drugs such 
as tianeptine are active even though they are thought to enhance serotonin reuptake, an 
effect opposite to the SSRI antidepressants (22-24). Neither can the hypothesis explain 
why the densities of some serotonin (5-HT) receptors are increased by long-term elec-
troconvulsive therapy, one of the most effective treatments of depression (25). More 
recently it has been proposed that there is a structural deficit in some serotonin receptors 
that are functionally involved in the regulation of mood (26). Nevertheless, despite these 
serious limitations, the monoamine hypothesis stimulated the development of safer 
antidepressants like the selective serotonin reuptake inhibitors (SSRIs), such as, citalo-
pram, fluoxetine, fluvoxamine, paroxetine and setraline, the selective noradrenaline 
reuptake inhibitors and the dual action antidepressants, venlafaxine and milnacipran, 
that modify both central noradrenergic and serotonergic systems (27). 
Role of current antidepressants 
Pharmacotherapy has been the main treatment strategy for depression over the past 40 
years. Up to 1980, tricyclic antidepressants (TCAs) represented the major pharmacol-
ogical treatment for depression. The TCAs differ from each other in their potency to 
inhibit presynaptic noradrenaline or serotonin uptake and in their propensity for causing 
variety of untoward effects (28). Thus they induce anticholinergic, antihistaminergic 
and cardiotoxic side effects related to their antagonistic action mainly on muscarinic M1, 
histamine H1 and adrenergic-α1 receptors and cardiac Na+ and Ca+ channels (29-32). 
 The first generation of MAO-A inhibitors also induced severe side effects such as 
hypertensive crises because of the irreversible inhibition of MAO-A that catabolises the 
monoamines. Therefore, the selective and reversible second generation of MAO-A 
inhibitors such as moclobemide was developed (33), drugs that were less likely to 
permit the passage of dietary monoamine through the wall of the gastrointestinal tract. 
 Nowadays, the SSRIs are most widely used in clinical practice. Zimelidine was the 
first specific SSRI but was withdrawn from the market due to its serious intestinal side 
effects. This was replaced by fluoxetine and fluvoxamine (28). All the SSRIs (fluoxet-
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ine, setraline, paroxetine, fluvoxamine, and citalopram) selectively block the reuptake of 
serotonin centrally and thereby resulting in an increase of serotonin in the synaptic cleft 
(34-36). Though SSRIs take approximately 2 weeks to increase the serotonin neuro-
transmission (37, 38), these are well tolerated and safe. 
 Recently, serotonin and noradrenaline reuptake inhibitor venlafaxine and milnacip-
ran were introduced (28). Venlafaxine has a predominantly inhibitory effect on the 
serotonin transporter at low doses but inhibits the uptake of both serotonin and 
noradrenaline at high doses. Conversely milnacipran blocks the noradrenalin transporter 
at low doses but inhibits the uptake of both monoamines at high doses (39). 
 More recently, several selective 5-HT1A receptor agonists have been available but 
the antidepressant efficacy is limited (40, 41). The 5-HT2 receptor antagonist nefa-
zodone also shows low antidepressant efficacy (42). 
 The tetracyclic antidepressants, mianserin and mirtazepine differ from the different 
types of reuptake inhibitor antidepressants in that they primarily act by enhancing the 
release of noradrenaline by blocking the presynaptic alpha-2 adrenoceptors on the 
presynaptic nerve terminals. Mirtazepine, an analogue of mianserin, has an additional 
property in that it also enhances the release of serotonin. While these antidepressants 
lack many of the untoward side effects of the reuptake inhibitors they are potent H1 
antagonists, thereby causing sedation, and are also more likely to cause weight gain. 
 Despite all these different types of antidepressants that are now available, the 
efficacy in treating depression has not noticeably improved since the introduction of 
imipramine in 1958. In addition, the rate of relapse and the frequency of recurrence are 
still far too high. Clearly there is a need for more effective antidepressants. 
Recent hypotheses of depression 
Hypothalamic-Pituitary-Adrenal (HPA) Axis 
The association between abnormality of HPA axis and depression has long been known 
(43). There were well documented abnormalities of HPA axis function in depressed 
patients, such as, enhance 24-hour urinary free cortisol and raised serum cortisol levels 
(44-47), impaired dexamethasone suppression (48, 49), and blunting of adrenocortico-
trophic hormone (ACTH) release in response to corticotrophin-releasing factor (CRF) 
challenge (50, 51). During the last decade, more evidence has been produced to link 
chronic stress or stressful life events such as loss of parents (52) and child physical or 
sexual abuse (53) with the onset of depression and its severity (54-56). It has been 
suggested that such events might cause long-lasting alterations in corticotrophin releas-
ing factor (CRF) containing neurones, thereby increasing an individual’s vulnerability 
to stressors later in life (57). 
 The neuroendocrine response to any stressor is mediated through the HPA axis. 
This cascade begins in the central nervous system with increase release of CRF from the 
hypothalamus into the portal vasculature (58), to act on anterior pituitary CRF receptors. 
The anterior pituitary gland responds by stimulating the release of adrenocorticotrophic 
hormone (ACTH), which stimulates the synthesis of cortisol from the adrenal cortex. In 
addition, arginine vasopressin (AVP) has recently been established as a co-secretagogue 
to CRF, which is co-expressed with CRF in situations of stress (59). It acts on anterior 
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pituitary AVP receptors and produces a major increase in ACTH release by synergistic 
interaction with CRF at the second messenger level. 
 Two hypotheses have been proposed as pathophysiological explanations for the 
HPA overactivity observed in depression. The first involves increased brain CRF 
driving the HPA axis into “overdrive” (60); it is suggested that CRF may provide a link 
between the monoamine and neuroendocrine theories of depression since CRF appears 
to regulate tyrosine hydroxylase, the rate limiting enzyme in the synthesis of noradrena-
line (61). The second hypothesis suggests impaired negative feedback at both the 
pituitary corticotroph and central glucocorticoid receptor levels (62) and it is proposed 
that a primary alteration in glucocorticoid receptor (GR) or mineralocorticoid receptor 
(MR) number or function may contribute to the pathophysiology of depression (63). 
However, a study by Dinan and co-workers (64) suggests there is a switch from CRF to 
AVP regulation of HPA axis during depression, implying that a CRF antagonist would 
be unlikely to correct the HPA disturbance observed in depression whereas a blockade 
of AVP receptor might offer a more appropriate pharmacological approach (58). 
Other neuroendocrine axis and non-amine neurotransmitters 
It is well documented that hypothyroidism can lead to major depression and could be 
reversed by thyroxine treatment (65). There is some evidence of a dysfunction of the 
hypothalamic-pituitary-thyroid (HPT) axis in major depression. In some patients with 
major depression, slightly elevated thyroxine (T4) levels (66), a blunted response of 
thyroid stimulating hormone (TSH) to thyrotropin-releasing hormone (TRH) (66, 67), 
and loss of normal nocturnal surge in TSH levels (68) are reported. Decrease in T4, and 
free T4, levels after antidepressant treatment is also reported (69). 
 There are other non-amine neurotransmitters that are hypothesised to be involved in 
pathophysiology of major depression. Recently, an antagonist of substance P, a co-
transmitter with serotonin (neurotransmitter) involved in the transmission of pain, has 
been reported to have antidepressant qualities in placebo-controlled trial in patients with 
moderate to severe depression (70). The involvement of gamma-amino-butyric acid 
(GABA) and glutamatergic neurotransmission in pathophysiology of depression is also 
proposed (71, 72). 
 A neurotrophic factor, brain derived neurotrophic factor (BDNF) is also proposed to 
be involved in pathophysiology of depression. An experimental study demonstrated that 
centrally administered BDNF attenuated the depressive behaviour (73). In addition, 
chronic antidepressant treatment has been shown to increase BDNF expression, particu-
larly in the hippocampus (74, 75). 
Neurogenesis and neuroplasticity hypotheses 
The neurogenesis hypothesis (76) proposes that (the adult) neurogenesis is impaired in 
depression and is responsible for the hippocampal structural changes (77), which is 
reversible in the remission stage of the disease (78). It has been shown in some studies 
that treatment with antidepressants (79, 80), electroconvulsive therapy (ECT) (81, 82), 
and increased physical activity (83), can stimulate the proliferation of hippocampal 
progenitor cells, which contribute to the first stage of adult neurogenesis. Enhanced 
activity of the serotonergic system has also been reported to improve adult hippocampal 
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neurogenesis (84). However, in addition to the hippocampus, other regions in the brain 
also show changes in depression. The alterations in prefrontal neurons and glial cell 
numbers (85), and substantially reduced glial cell density in the amygdale that are 
moderately improved by mood stabilizers (86) , are also reported to occur in major 
depression. Moreover, in major depression, there are changes in other neurotrophic 
factors such as BDNF that can influence the neuronal plasticity. 
 Based on above factors, severe and chronic disturbance of cellular plasticity, includ-
ing reduced neurogenesis, forms the basis of the neurogenesis and cellular plasticity 
hypothesis of major depression (87). However, whether these changes are the cause or 
consequence of depression is presently unclear. In addition, the mechanism whereby 
adult neurogenesis and plasticity could be involved in major depression and how this 
hypothesis can be applied diagnostically is unclear. 
Macrophage theory of depression and role of inflammatory changes 
The macrophage theory of depression (88) is the first theory that brings the role of 
immune system and inflammatory changes into pathophysiology of depression. In this 
hypothesis, interleukin (IL)1β, which is secreted from the macrophages, directly stimu-
lates the CRF secretion in the hypothalamus and induces hyperactivity of the HPA axis. 
This theory therefore links the immune system with the neuroendocrine and neuro-
transmitter changes in major depression. 
 It is well documented that acute infections, in both animals and man, are usually 
accompanied by a cluster of non-specific symptoms which include fever, hypersomnia, 
hyperalgesia, anorexia, anhedonia, memory defects and depressed behaviour (89). Since 
the release of pro-inflammatory cytokines such as IL1β, IL6 and tumour necrosis factor 
(TNF)α are an integral part of the host response to infection, these cytokines are consid-
ered to play a pivotal role in neurotransmitter and neuroendocrine changes. The stimula-
tion of HPA axis by IL1 thereby increases the secretion of ACTH from the anterior 
pituitary and glucocorticoids from adrenals (90). There is also evidence that IL1 can 
increase the turnover of serotonin in vivo in some regions of the rat brain (91) as shown 
by an increase in the steady-state concentration of the main metabolite, 5-
hydroxyindoleaccetic acid (5HIAA). Moreover, IL1 also induces an increase in the 
functional activity of central noradrenergic system. Thus in the several mesolimbic 
regions of the rat brain, IL1 increases the concentration of the main metabolite of 
noradrenaline, 3-methoxy-4-hydroxyphenyl-glycol (MHPG) (92). 
 Experimentally it has been shown that the systemic injection of lipopolysaccharide 
(LPS), obtained from the bacterial cell wall and a strong inducer of the synthesis and 
release of pro-inflammatory cytokines, also produces depression like “sickness behav-
iour” that is largely attenuated by the prior administration of IL1 antagonist IL10 (93). 
In human studies it has been shown that the interferon (IFN), the cytokine used to treat 
certain cancers and viral infections, can induce depression. In short term applications of 
high doses of IFNα given intravenously, 20 to 60 percent of patients developed organic 
mental disorders after short latency period of several days but symptoms generally 
subside promptly after cessation of treatment (94-101). Compared to the side effects 
occurring in high-dose therapy, neuropsychiatric effects during low-dose therapy are 
reported to be less severe and occur after a longer latency in 4 to 16 percent of patients 
(102). 
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 It is well established that major depression is associated with dysregulation of 
immune mediators. These changes include the rise in IL1β, IL6, IL12, soluble IL6R, 
IL2, soluble IL2R, IL1Ra, IL10 and IFNγ (103-110). There is also evidence from in 
vitro studies that when human monocytes are incubated with different classes of antide-
pressants together with LPS that stimulates the release of pro-inflammatory cytokines, 
the release of IL1, IL6 and TNFα are markedly inhibited (111). The enhanced lympho-
cyte proliferation and stimulated synthesis of IL1 and IL2 from spleen cells that occurs 
in the rats subjected to chronic mild stress is also reversed following chronic treatment 
with imipramine (112).Other studies show that antidepressants can induce increases in 
anti-inflammatory cytokine IL10 and a decrease in IFNγ (113, 114). 
 However, there is some controversy regarding the anti-inflammatory effect of 
different types of antidepressants. Changes produced in rats following an acute chal-
lenge with LPS, such as a reduction in the body weight and food consumption, and a 
reduction in intake of saccharine flavoured water, have been shown to be reversed by 
the chronic treatment with a tricyclic antidepressant but not with venlafaxine or a SSRI 
(115). These findings are supported by another in vivo study in which desipramine has 
been shown to impair the secretion of both IL1 and TNFα following a challenge with 
LPS, while no effect has been observed with venlafaxine or paroxetine (116). However, 
in olfactory bulbectomised (OBX) rat model of depression, it has been shown that the 
elevated acute phase protein response is attenuated by both tricyclic antidepressants and 
SSRIs (117). Moreover, SSRIs have been shown to decrease the release of IL6 and 
acute phase proteins in patients with major depression (118). 
 As IL1 could indirectly increase the synthesis of inflammatory mediator pros-
taglandin (PG) E2 (119), the increased PGE2 concentration in the saliva, blood and 
cerebrospinal fluid of depressed patients has also been documented (120-123). Based on 
these findings the inhibitory activity of antidepressants on cyclo-oxygenase (COX) 
which is involved in synthesis of inflammatory mediator, PGE2, has been proposed as a 
mechanism of antidepressant action in reducing the inflammatory changes (124). The 
role of omega-3 fatty acid against PGE2 and omega-6 fatty acid is also proposed in 
macrophage theory of depression (88) and animal studies have provided a possible 
mechanism for the role omega-3 fatty acid in depression (125-127). These studies 
support the possible beneficial effects of COX2-inhibitors (128) and omega-3 fatty acid 
(129-132) as putative antidepressants. Moreover, during the last decade, the enhancing 
effect of pro-inflammatory cytokines on the enzyme indoleamine 2,3-dioxygenase 
(IDO) that in turn enhances the tryptophan catabolism which might results in low 
serotonin synthesis also becomes of interest (133-137). 
 Thus the involvement of the pro-inflammatory cytokines in pathophysiology of 
depression is well confirmed. Several mechanisms are proposed through which blood-
borne cytokines to reach target receptors in the brain. The active transport mechanism, 
transport across circumventricular organs, transport by binding to the receptors in the 
blood vessels that course through the brain and retrograde transport of cytokines 
through the vagus nerve have been proposed (138). The role of IL1 and TNF in neu-
ronal injury is also documented. These pro-inflammatory cytokines have both protective 
and degenerative effects on the neurons and glia depending on their concentrations and 
duration of exposure (139). 
 These observations raise a question whether depression is a neurodegenerative 
disease induced by chronic inflammation. In addition, how those immune changes and 
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monoamine changes are linked to each other in an integrated mechanism in the patho-
physiology of depression also becomes an important problem of research. Moreover, the 
specificity of the immune changes in depression is unclear as is the possible role of 
coping mechanisms. These are some of the questions that need to be addressed. This 
thesis will seek to address some of the questions raised by the neurodegeneration 
hypothesis of depression.  
 
 
Figure 1. Stress induced immune activation and its link to neuroendocrine and neurotransmitter changes 
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Summary 
There are different theories and hypotheses related to the aetiology of depression. The 
interaction between brain 5-HT level and the activity of its autoreceptors plays a role in 
mood changes and depression. In major depression, activation of the Inflammatory 
Response System (IRS) and, increased concentrations of proinflammatory cytokines, 
prostaglandin E2 and negative immuno-regulatory cytokines in peripheral blood have 
been reported. Recently, pro-inflammatory cytokines have been found to have profound 
effects on the metabolism of brain serotonin through the enzyme indoleamine 2,3-
dioxygenase (IDO) that metabolizes the tryptophan, the precursor of 5-HT to neurode-
generative quinolinate and neuroprotective kynurenate. The cytokine-serotonin interac-
tion that leads to the challenge between quinolinate and kynurenate in the brain explains 
the neurodegeneration hypothesis of depression. 
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Introduction 
Stress is originally an engineering term introduced to human physiology by Hans Syle 
in 1936 as any condition that seriously perturbs the physiological and psychological 
homeostasis of an organism. None of the living creature is free from stress. If the 
stressful situation, regardless of the type whether physical or psychological, continues 
over a period of time, well adjusted under stress state or depression in human beings and 
sickness behaviour in animals can occur. Depression, a pain of mind is the most terrible 
suffering of mankind more than all the bodily pain. Scientists had done many research 
studies on depression and there are theories and hypotheses related to the aetiology of 
depression. 
 The depression-prone subjects have a vulnerable serotonergic system (1). In times 
of stress, more 5-HT is necessary for coping the stress and though up-regulation of 5-
HT2 receptor occurs as a compensatory mechanism, 5-HT turnover dysfunction occurs 
and major depression develop after long-term melancholia (2). Since tryptophan is the 
precursor of 5-HT, tryptophan depletion also has depressogenic effect (3). 
 The relationship between psychiatric illness and immune system was first observed 
in 1927 by Wagner-Jauregg, the only psychiatrist who ever awarded Noble prize for his 
work on malaria inoculation in dementia paralytica (4). During recent years, many 
studies have been carried out on the relationship between psychological stress, depres-
sion and immune system (5-8). In major depression, activation of the Inflammatory 
Response System (IRS) and, increased concentrations of proinflammatory cytokines, 
prostaglandin E2 and negative immuno-regulatory cytokines in peripheral blood have 
been reported (9-12). In animals, different stressors are reported to increase interleukin-
1 messenger RNA expression in the hypothalamus (13), elevate interleukin-1 activity in 
cell culture supernatants (14), and enhance biologically active interleukin-1 in the 
hypothalamus (15), increase stimulated production of interleukin-1β and TNF-α by 
isolated alveolar macrophages (16), or increase plasma concentrations of interleukin-6 
(17, 18). 
 Recently, the link between cytokines and the serotonergic turnover has been ex-
plored. It was reported that cytokines such as IL1β, IL2 and IFNγ reduce the production 
of 5-HT by stimulating the activity of indoleamine 2,3-dioxygenase (IDO), an enzyme 
which converts tryptophan, the precursor of 5-HT to kynurenine (19, 20). The 
kynurenine is again metabolized (21) into quinolinic acid (quinolinate) and kynurenic 
acid (kynurenate), the excitotoxic NMDA receptor agonist (22) and the antagonist of all 
three ionotropic excitatory aminoacid receptors (23), respectively. Therefore, it is 
proposed that overexpression of IDO leads to depletion of plasma tryptophan and 
reduced synthesis of 5-HT in the brain, which finally may induce serotonin-depletion 
related disorder such as major depression. The involvement of the interaction between 
cytokine and serotonergic system through IDO and tryptophan degradation pathway 
beyond IDO in stress and depression still need exploration. 
 After reviewing the hypotheses, a question is raised why some people could adapt 
the stress well while the others undergo depression and it brought this hypothesis which 
emphasizes the balance between neurodegeneration and neuroprotection as a result of 
tryptophan degradation following the cytokine-serotonin interaction through the enzyme 
IDO.  
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Serotonin and depression 
The monoamine hypothesis of depression proposed that low levels of one or more of the 
brain monoamine neurotransmitters; serotonin, noradrenaline and dopamine could 
produce depression. This hypothesis is again refined in a way that depressive illness 
may arise, specifically, from decreased brain serotonin (5-HT) function (24). The 
subsequent evidences that the level of 5-HT precursor tryptophan was decreased in 
depressed patients (25), mood lowering effects occurred after administration of trypto-
phan-free diet (3), and the administration of tryptophan produced an antidepressant 
effect (26) supported the hypothesis. 
 The 5-HT system is also influenced by the terminal autoreceptors. Out of five 
different subtypes of 5-HT receptors, three of them, namely, 5-HT1B, 5-HT1D and 5-
HT1A autoreceptors are known to be involved in depression. It is well established that 
the release of 5-HT into the synapse of serotonergic neurons is also under the control of 
those autoreceptors, and acute blockade of these receptors could result in enhanced 
extracellular 5-HT levels and, hence, antidepressant activity. These autoreceptors were 
thought to be 5-HT1B receptor subtype and the introduction of selective 5-HT1B 
receptor antagonist confirmed this in both rodent and human brain (27, 28). The 5-
HT1B and 5-HT1D autoreceptors are found to be present in dorsal raphe nucleus (DRN) 
and can modulate 5-HT levels within this brain region (29, 30). 
 Regarding the link of 5-HT2A receptor to depression, recent experiments have 
shown that these receptors may mediate some of the antidepressant effects seen in 
putative animal models of anxiety and depression (31). In time of stress, more 5-HT is 
needed to cope with demands and upregulation of 5-HT2 receptors is a compensatory 
response to maintain 5-HT turnover. Ultimately, however, 5-HT turnover dysfunction 
occurs and major depression will develop, in the longer term followed by melancholia 
(2). The newer antidepressants are developed to modify the serotonergic system such as 
selective serotonin reuptake inhibitors, serotonin and noradrenalin reuptake inhibitors, 
5-HT2 receptor antagonists and 5-HT1A receptor partial agonists and are reported to be 
effective in treatment of depression (32). Taken together, it is clear that the interaction 
between brain 5-HT level and the activity of its autoreceptors plays a role in mood 
changes and depression. 
Cytokines and depression 
The cytokines are a diverse group of proteins that may be regarded as the hormones of 
the immune system. The interaction among the pro-inflammatory cytokines (IL1β, IL6, 
IL8, TNFα) can result in synergistic activities in both cytokine production and cytokine 
activities. Pro-inflammatory cytokine interactions are also associated with a synergistic 
induction of neurological and psychiatric manifestations (33). Another category of 
cytokines known as anti-inflammatory cytokines (IL1Ra, IL4, IL10, TGFβ1) can 
antagonize the actions of pro-inflammatory cytokines. There are two components of 
cytokine balance. The first is the balance within a cytokine system like IL1 increases the 
synthesis and secretion of IL1Ra, the up-regulation of which is proposed to attenuate the 
deleterious effect of IL1 by blocking the IL1 receptor (34). The second is the balance 
among different cytokine systems like TGFβ1 inhibits IL1 and TNFα activities (35). 
 Most of the cytokines can be synthesized and released within the nervous system 
(36). Although most cytokines in the brain are secreted by astrocytes and microglia, 
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some evidence suggests that under certain conditions, neurons can also produce cyto-
kines (37). Within the brain, IL1 has been found in several brain regions including the 
hippocampus and specific hypothalamic structures such as the paraventricular nucleus 
and arcuate nucleus. IL1 immunoreactive nerve fibres have also been described in the 
human brain, particularly in the hypothalamus (38). Widespread TNF and other cyto-
kine immunoreactivity have been detected in the murine brain (39). Human astroglial 
cell line stimulated by IL1 has been shown to produce colony stimulating factor, TNFα, 
additional IL1, and IL6 (40, 41).  
 There is a growing body of circumstantial evidences that suggests that major 
depression is associated with dysregulation of immune mediators such as rise in IL1β, 
IL6, soluble IL6R, IL2, and soluble IL2R (42, 43). The increased IL1Ra level was also 
reported in patients with major depression (44). It was proven that the antidepressants 
can decrease the IFNγ/IL10 ratio which might be partly due to increase in anti-
inflammatory cytokine, IL10 (45). It has been hypothesized that cytokine hypersecretion 
may be involved in the pathophysiology of depressive disorders (46). In addition, a pro-
inflammatory cytokine, IL12 is found to be suppressed by antidepressive drugs (12). 
Moreover, recent animal and human studies have shown that the psychological stressor 
such as immobilization, open field, speech task and academic exam can elicit an activa-
tion of inflammatory response system (5, 8, 9, 47). In integrative term, a balance be-
tween pro-inflammatory cytokines and anti-inflammatory cytokines plays a role in 
appropriate modulation of cellular responses in the brain in psychological stress and 
depression.  
Cytokine-Serotonin interaction in depression 
Recently, pro-inflammatory cytokines have been found to have profound effects on the 
metabolism of brain serotonin, dopamine and noradrenalin in mice and rats (48). In 
clinical studies, significant decrease in serum tryptophan concentration has been noted 
in patients receiving IL2 or IFNα (49, 50). There are two major mechanisms involved in 
cytokine-induced tryptophan depletion. The first mechanism is that cytokine may 
induce TRP depletion directly by reducing food intake (33, 51), since TRP levels are 
strongly modulated by dietary intake (52). The second mechanism is that cytokines 
induce TRP depletion by enhancing the activity of indoleamine 2,3-dioxygenase (IDO), 
the first enzyme in the kynurenine pathway, that degrades and converts TRP to 
kynurenine (53, 54).  IDO is the enzyme active not only on L-tryptophan but also on L- 
and L-5-hydroxytryptophan, 5-HT, and melatonin (55) and is widely distributed in the 
intestinal tissues, lungs, placenta and the brain. It was observed that IFNγ, TNFα, IL1 
and IL2 can enhance IDO activity (56-60). 
 The Kynurenine is again metabolized into kynurenic acid, quinolinic acid and 
anthranilic acid (Fig-1) by kynurenine aminotransferase, kynurenine 3-monooxygenase 
(kynurenine 3-hydroxylase) and kynureninase, respectively (61). Both kynurenine 3-
monooxygenase and kynureninase are also shown to be activated by IFNγ and TNFα 
(62). The anthranilic acid is again metabolized into quinolinic acid, the excitotoxic 
NMDA receptor agonist (22) whereas kynurenic acid is the antagonist of all three 
ionotropic excitatory amino acid receptors (23). These products are the results of cyto-
kine-serotonin interaction through IDO enzyme that plays a pivotal role in tryptophan 
depletion in depression. 
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Figure 1—Figure showing the cytokine-serotonin interaction through IDO 
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Neurodegeneration hypothesis of depression 
Major depression is a recurrent illness, the interval between episodes tends to shorten 
while with each new episode there is an increasing risk for the occurrence of another 
(63). It is reported that the onset, recurrence and remission depend on childhood adver-
sity (64). It is also reported that depression is common in old age and especially among 
those in nursing home (65), and is common in those with chronic medical illness like 
coronary heart disease and diabetes (66), Parkinson’s disease (67), stroke (68) and 
cancer (69). Taken all above findings together, the depression is associated with aging, 
medical illness and chronic stress. 
 As it is mentioned, the cytokine-serotonin interaction through the enzyme IDO that 
results in tryptophan depletion into kynurenine pathway plays an important role in 
pathophysiology of depression. Chronic psychological stress or medical illness can 
result in rise of pro-inflammatory cytokines and than in tryptophan depletion and lead to 
depression in the end. A question is raised why some people who had undergone 
chronic psychological or physical stress could cope with that situation, and it brings the 
following neurodegeneration hypothesis (Figure-2). 
 
Figure-2 Neurodegeneration hypothesis of depression 
 
 The psychological stress induces tryptophan depletion by increasing in demand and 
mood changes develop. It was balanced by modification of serotonin synthesis and 
expression of different serotonin receptors. This is the first point how people cope with 
psychological stress. When the psychological stress continues over a period of time, the 
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increase of pro-inflammatory cytokines occurs. In case of physical stress or medical 
illness also, the pro-inflammatory cytokines increase. The adverse effects of pro-
inflammatory cytokines will be balanced by increase production of anti-inflammatory 
cytokines. The sickness behaviour will develop due to pro-inflammatory cytokines and 
it will relieve due to the second coping strategy, the balance between pro-inflammatory 
cytokines and anti-inflammatory cytokines. Because of these pro-inflammatory cyto-
kines, IDO enzyme is activated and further tryptophan depletion through kynurenine 
pathway occurs. As a result of this pathway, neurodegenerative quinolinate and neuro-
protective kynurenate are produced in the brain. Here is the third and important coping 
strategy, the challenge between neurodegeneration and neuroprotection. Normally, 
neurodegeneration process will be more pronounced to a certain extent and thus aging 
in terms of brain function occurs with age and degree of exposure to stress. If the 
balance between pro- and anti-inflammatory cytokines disturbed or stress continues 
further, the tryptophan degradation through kynurenine pathway becomes more pro-
nounced and the neurodegeneration-neuroprotection challenge becomes extensive. 
When this challenge shifts to degenerative side, pronounced neurodegeneration of areas 
of brain involved in neuroendocrinology of stress and memory such as hippocampus 
occurs. This neurodegeneration may also occur in other areas related to stress coping 
mechanism. Finally, the neurodegeneration disturbs all the coping strategies in the brain 
and result in major depression or treatment resistant depression. The neurodegeneration 
process will be reinforced by the neurotoxic effect of high cortisone level during stress 
(70, 71). 
 This neurodegeneration hypothesis is supported by the findings of Bremner and 
group (72) and Sheline and co-workers (73, 74) which stated the atrophy of hippocam-
pus in major depression that increases with longer duration of depression. It is also 
supported by the findings that adult neurogenesis occurs in brain structures that exhibit 
a high degree of neural plasticity such as hippocampus and olfactory bulb (75, 76) and 
olfactory bulbectomised rats show typical behavioural and biochemical changes in 
human depression (77). 
This hypothesis can explain how people cope with different stress at different stages 
according to severity and duration of stress and why major depression develops.     
Future Research Direction 
It is still necessary to confirm the neurodegeneration in major depression with stronger 
evidences. The factors influencing the biochemical pathway of tryptophan depletion are 
also necessary to be explored in more detailed. Moreover, the role of cytokine-serotonin 
interaction in other related psychiatric disorders is also an area to be explored in the 
future.  
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Aim of the thesis 
The general aim of this thesis is to find out whether our proposed hypothesis is true as 
part of the pathophysiological mechanisms of both experimental and clinical major 
depression. The specific objectives of this thesis are: to investigate the imbalance 
between pro- and anti- inflammatory cytokines in patients with major depression, to 
investigate the association between peripheral cytokine changes and central cytokine 
changes and depressive behaviour in rats and role of SSRI antidepressant, to investigate 
the association between peripheral cytokine and central inflammatory related morpho-
logical changes in rats and role of SSRI antidepressant, to investigate the role of anti-
inflammatory agent on peripheral and central cytokine changes and behaviour in animal 
model of depression, and to investigate the kynurenine pathway metabolites changes in 
major depression. 
Outline of the thesis 
The second part of the first chapter explained how the stress induced immune changes 
are related to brain amine changes that can induce acute depressive mood and how these 
immune changes can induce neuroprotection-neurodegeneration imbalance through 
kynurenine metabolism that can bring long term, chronic or treatment resistant depres-
sion. In Chapter 2, we investigated the pro- and anti-inflammatory cytokine imbalance 
in clinical major depression. In Chapter 3, we discussed on our findings on the relation-
ship between a pro-inflammatory cytokine IFNα induced peripheral and the central pro- 
and anti-inflammatory cytokines changes and behavioural changes in the rats and the 
preventive role of SSRI antidepressant, paroxetine. In Chapter 4, we mentioned about 
the peripheral IFNα induced brain inflammatory cells, astrocytes and microglia changes 
in the hippocampus of the rats and the preventive role of SSRI antidepressant fluoxetine. 
In Chapter 5, the results of the study on role of anti-inflammatory COX2 inhibitor 
celecoxib on immune and behavioural changes in OBX rat model of depression. The 
Chapter 6 is related to the findings that prove our hypothesis regarding the neuroprotec-
tion-neurodegeneration imbalance through kynurenine pathway in major depression. 
 In Chapter 7 we reviewed the inflammatory related changes in major depression 
and their relationship with inflammatory related changes in dementia. And the general 
discussion and future perspectives based on our findings were mentioned in the last 
chapter. 
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 Th1, Th2, and Th3 cytokine alterations 
in major depression 
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Abstract 
Background: Many studies have shown that the balance between Th1 cytokines and 
Th2 cytokines plays a role in modulation of cellular responses in the brain during 
psychological stress and psychiatric disorders. The Th3 cytokine, transforming growth 
factor beta-1 (TGFβ1), has been shown to regulate the balance between Th1 and Th2 
cytokines. However, the role of TGFβ1 in the psychoimmunology of depression has 
never been explored. 
Methods: A total of 40 depressed patients and 80 normal controls were recruited. The 
plasma levels of IFNγ, IL4, and TGFβ1 were studied at the time of admission and 8 
weeks after antidepressant treatment. 
Results: The proportion of patients who showed immunoreactivity to IFNγ and IL4 in 
the plasma, and the plasma IFNγ /IL4 ratio, were significantly higher in depressed 
patients than in controls. The IFNγ/TGFβ1 ratio was also higher in depressed patients, 
and TGFβ1 levels showed a significant negative correlation with the HDRS depression 
scale. After treatment, TGFβ1 level increased significantly, and the IFNγ/IL4 ratio 
decreased significantly, in the patient group. However, Th1 changes in male and female 
showed different trend such as Th1 arm was decreased after the treatment in all male 
whereas it was increased in premenopausal age women. 
Limitations: Replication and extension using a larger sample size are required. 
Conclusions: The Th1 and Th2 cytokine imbalance was observed in subpopulation of 
depressed patients. TGFβ1 seemed to play a role in the pathophysiology of depression 
in this population. Moreover, antidepressant treatment was found to affect the Th1/Th2 
balance through the action of TGFβ1. 
 38 
 CYTOKINE ALTERATIONS IN MAJOR DEPRESSION 
Introduction 
The relationship between endogenous psychoses and T and B lymphocytes was first 
observed by a group of Russian clinicians in 1980 (1). Since then, many studies have 
focused on lymphocyte activities and psychiatric disorders (2-5), the change in cyto-
kines in psychiatric disorders (6-10) and the presence of cytokines in the brain (11). 
Based on the macrophage theory of depression (12), circumstantial evidence was 
provided that major depression is associated with dysregulation of immune mediators, 
such as the rise in IL1β, IL6, IL12, soluble IL6R, IL2, soluble IL2R, IL1Ra and IFNγ 
(13-19). These changes have been considered in terms of the imbalance between indi-
vidual pro- and anti-inflammatory cytokines and the Th1 and Th2 imbalance in major 
depression. It was observed that antidepressants can decrease the IFNγ/IL10 ratio, partly 
due to an increase in the anti-inflammatory cytokine, IL10 (20). IFNγ is produced 
mainly by T-helper type 1 (Th1) cells and NK cells (21), and IL10 is produced mainly 
by Th2 cells (22). Taken together, many studies suggest that an imbalance between Th1 
cytokines and Th2 cytokines or pro-inflammatory and anti-inflammatory cytokines 
plays a role in the appropriate modulation of cellular response in the brain during 
psychological stress and psychiatric disorders (23-26). 
Recently, it was proposed that there are populations of regulatory T cells, some desig-
nated Th3, that exert their action primarily by secreting transforming growth factor 
beta-1 (TGFβ1). In the past, role of this cytokine in immune tolerance was largely 
discussed in oral tolerance (27). The action of this cytokine was shown to suppress 
production of Th1 cytokines, such as interferon-γ (IFNγ), tumour necrosis factor-α 
(TNFα), IL2, and IL2R and was found in the eyes, placenta, testis, central nervous 
system and adrenal cortex (28, 29). Even though the major role of TGFβ1 was discussed 
in terms of oral tolerance, since it was also found in central nervous system and adrenal 
cortex, another possible role for this cytokine in maintaining the Th1 and Th2 balance in 
depression. However, the role of TGFβ1 in relation to the psychoimmunology of de-
pression has never been explored. 
In this study, we explored the role of 3 cytokines, IFNγ, IL4, and TGFβ1, which repre-
sent the cytokines of the Th1, Th2, and Th3 types, in major depression. Cytokine levels 
were measured at the time of admission and 8 weeks after effective antidepressant 
treatment. Our results suggested that the Th3 cytokine, TGFβ1 certainly have a role in 
psychoimmunology of depression. 
Subjects and Methods 
Subjects 
Among psychiatric patients admitted to the Psychiatry Department, Korea University 
Medical Centre, from August 1999 to September 2002, 40 patients with major depres-
sion who met the Diagnostic and Statistical Manual (DSM-IV) criteria (30) based on 
clinical interviews using a Structured Clinical Interview for DSM-IV (31) were re-
cruited. All patients were either medication-naïve (first-onset) or medication-free for at 
least 4 months. This study was approved by the institutional ethical committee of Korea 
University. 
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 The psychopathological status of the patients was assessed by a trained physician 
(Y-K Kim) using the Brief Psychiatric Rating Scale (BPRS) (32) and the Hamilton 
Depression Rating Scale (HDRS) (33) on admission and 8 weeks later.  
 Twenty-two of 40 patients completed the 8-week study. Among them, 8 were 
treated with paroxetine (mean, 33.7 mg; range, 20-40 mg), 6 with fluoxetine (mean, 
36.6 mg; range, 20-60 mg), 5 with nefazodone (mean, 390 mg; range, 200-600 mg), and 
3 with venlafaxine (mean, 175 mg; range, 150-225 mg). Six patients were also given an 
antipsychotic medication (risperidone or olanzapine) for controlling psychotic symp-
toms. 
 Patients who had history of any concomitant psychiatric illness, such as substance 
or alcohol abuse, or history of infection or known autoimmune disease were excluded. 
Patients were found to have a normal blood and urine tests, be free from venereal 
diseases and have normal electrocardiogram (ECG) and electroencephalogram (EEG). 
The laboratory tests were rechecked after 8 weeks. 
 Eighty healthy age and sex matched controls (1 patient: 2 controls) were recruited 
among healthy individuals who visited the same hospital for regular health screening 
during the same period. Those with any history of psychiatric illness, diagnosed auto-
immune disease, or substance or alcohol abuse were excluded. All subjects were free 
from any physical illness within the 2 weeks before the study. They showed normal 
laboratory findings in blood chemistry, renal, thyroid and liver function, VDRL tests, 
chest X-ray, ECG, and EEG. 
Methods 
Fasting venous blood (10 ml) was withdrawn with a lithium heparin vacuum tube 
between 8:00-9:00 A.M. Plasma was separated immediately and stored at –70ºC. For 
the depressed patients, blood was sampled again at 8 weeks later. 
 Human cytokines IL4, IFNγ, and TGFβ1 were assayed using DuoSet ELISA De-
velopment System (R&D Systems, UK). All assays were carried out in duplicate by the 
same operator using the recommended buffers, diluents, and substrates. The IFN-γ 
ELISA was established with a detection range from 2 pg/ml to 500 pg/ml, and the intra- 
and inter-assay coefficients of variation were 6.7% and 9.2%, respectively. The IL4 
ELISA was established with a detection range from 3.0 pg/ml to 1000 pg/ml, and the 
intra- and inter-assay coefficients of variation were 5.6% and 7.08%, respectively. The 
TGFβ1 ELISA was established with a detection range from 50 pg/ml to 2500 pg/ml. 
This assay was performed on plasma samples activated with acidic solution since 
TGFβ1 is secreted mainly in latent forms (34). The intra- and inter-assay coefficients of 
variation were 5.3% and 9.8%, respectively. The cytokine assays were carried out in 
Cellular Neuroscience Division, Psychiatry and Neuropsychology Department, Faculty 
of Medicine, University of Maastricht. 
Statistical analysis 
The comparisons of demographic data, percent of subjects with cytokine immunoreac-
tivity in plasma, and TGFβ1 values between normal control and patient group were 
done using Student’s t-test and Chi-square test. The IFNγ, IL4 values and Th1/Th2 and 
Th1/Th3 ratios between the patients and control and between the patient groups before 
and after treatment were compared by non-parametric statistics. Pearson’s product 
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moment correlation coefficients were calculated to examine the relationships between 
the cytokine levels and clinical variables. The null hypothesis was rejected at P<0.05. 
Results 
Demographic data 
Table 1. Demographic data of the study subjects 
 Major depression  (n=40) Normal controls (n=80) 
Sex (male/female) 13/27 26/54 
Age (years) 40.7±15.5 
(17-65) 
40.3±13.1 
(17-64) 
BMI(kg/m2) 21.4±2.5 22.0±2.7 
Age of onset (years)  38.9±17.0 
(17-54) 
 
Duration of total illness (months) 22.1±33.6 
(1-144) 
 
Duration of current episode (months) 
 
1.9±1.2 
(1-4) 
 
Numbers of previous admission (n) 0.5±1.0 
(0-4) 
 
Numbers of episodes (n) 1.5±1.1(1-7)  
Family history (yes/no) 5/35  
Medication status on admission:   
   Medication-naïve 19  
   Medication-free 21  
Subtypes:   
     melancholic  25  
     Atypical 9  
     psychotic  6  
 Psychopathology scores#:    
   BPRS at admission  16.1±7.8  
   BPRS at 8 weeks  4.3±4.1  
   HDRS at admission  23.7±7.6  
   HDRS at 8 weeks 5.6±4.2  
 
# The psychopathological scores were based on the Brief Psychiatric Rating Scale (BPRS) and the Hamilton 
Depression Rating Scale (HDRS).  
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Table 1 lists the demographic data of the 122 study subjects. There were no significant 
differences in the male:female ratio between MDD and normal control groups (χ2=0.03; 
df=1; P=0.5), and there were no significant differences in body mass index (BMI) 
between the groups (t=0.7; df=120; P=0.40). There was also no significant difference in 
age between the MDD and normal control groups. 
Plasma IFNγ, IL4, and TGFβ1 levels in MDD patients and normal controls 
 In this part of the study, only pre-treatment cytokine levels were considered, so all 
40 enrolled patients were included. IFNγ was detectable in 18 MDD patients (45%) and 
4 normal controls (5%) (p<0.01) while IL4 was detectable in 38 MDD patients (95%) 
and 42 normal controls (52.5%) (p<0.05). A total of 20 MDD patients (50%) and 36 
normal controls (45%) showed only IL4 to be detectable but IFNγ, not. TGFβ1 was 
detected in all patients and control subjects. For the purpose of analysis, only the pa-
tients and controls with detectable cytokine levels were included. IFNγ and IL4 levels of 
MDD showed no difference from the controls but TGFβ1 showed a slight decrease 
(Table 2). However, IFNγ/IL4 (Th1/Th2) and IFNγ/ TGFβ1 (Th1/Th3) ratios were 
significantly higher (p<0.001) in depressed patients. TGFβ1 was negatively correlated 
with HDRS score (r=-0.41, p=0.006). There were no significant correlations between 
IL4, IFNγ, and TGFβ1 levels and any other clinical variable including age, duration of 
illness, age of onset, number of admissions, number of episodes, or psychopathology 
score (data not shown). There were no significant differences in the cytokine levels 
between male and female. 
 
Table 2. Plasma IFN-γ, IL4, and TGFβ1 levels in the study subjects who showed plasma immunoreactivity to 
all Th1, Th2 and Th3 cytokines. 
 Major depression 
 (n=18) 
Normal controls 
  (n=3) 
Statistics 
IFN-γ  41.28±20.2 pg/ml  82.1±124.39 pg/ml  Z=0.51; p=0.65 
IL4 10.92±1.04 pg/ml 21.67±20.73 pg/ml  Z=0; p=1 
TGFβ1 13.21±7.6 ng/ml  22.1±7.6 ng/ml  Z=-1.66; p=0.09  
IFN-γ / IL4 1.7±2.3  0.2±1.1 Z=-3.944; p<0.0001 
IFN-γ / TGFβ1  1.6±2.3 0.1±1.0  Z=-5.51; p<0.0001 
n.s = not significant 
Changes in IFN-γ, IL4, and TGFβ1 before and after treatment 
Twenty-two MDD patients completed the 8-week trial and were included in a second 
analysis. The changes in the cytokine levels between pre-treatment and post-treatment 
were analyzed by Wilcoxin Signed Rank test. There were no significant changes in 
IFNγ though the absolute values have increased. However, TGFβ1 and IL4 values were 
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significantly higher after treatment (Table 3). The IFNγ/IL4 (Th1/Th2) ratio decreased 
significantly (p<0.05), but the IFNγ/ TGFβ1 (Th1/Th3) ratio did not change. When the 
role of gender was considered, all male patients with detectable pretreatment IFNγ 
values showed reduction in IFNγ after treatment though 66.67% of female (age ranged 
21 years to 34 years) showed increase in IFNγ and 33.33% of female (age ranged 55 
to57 years) showed decrease after treatment (p<0.05). When absolute values were 
considered, there was a trend showing that female patients had higher IFNγ values after 
treatment (z=-1.87, p=0.06). However, there was no difference in IL4 and TGFβ1 
changes since all showed decrease in IL4 and an increase in TGFβ1 after treatment. 
There were no significant correlations between the changes of the cytokines levels and 
the changes of the HDRS or BPRS total scores (data not shown). 
 
Table 3. Changes of plasma IFN-γ, IL4, and TGFβ1 levels before and after 8 weeks of treatmentin patients 
who showed plasma immunoreactivity to all Th1, Th2 and Th3 cytokines. 
 Before treatment 
(n=10) 
After treatment 
(n=10) 
Statistics 
IFN-γ 19.8±26.7 pg/ml  14.2±24.6 pg/ml  Z=-0.889; n.s. 
IL4 11.2±7.2 pg/ml 9.2±2.1 pg/ml        Z=-2.306; p<0.05 
TGFβ1 17.7±10.3 ng/ml 25.8±7.4 ng/ml Z=-2.549; p<0.01 
IFN-γ / IL4 2.1±1.7 1.2±1.5 Z=-1.511; p<0.05 
IFN-γ TGFβ1 1.3±1.6 0.8±1.4 Z=-0.357; n.s. 
n.s = not significant 
Discussion 
Our data demonstrated that among the depressed patients nearly 50% showed high pro-
inflammatory cytokine activity. Moreover, the results showed depressed patients had 
higher plasma cytokine levels of both Th1 and Th2 subsets but plasma Th3 cytokine 
showed a trend to be lower compared to normal controls. The Th1/Th2 and Th1/Th3 
ratios were also significantly higher in patients than normal controls. In addition, the 
plasma Th3 cytokine, TGFβ1 level was negatively correlated with the HDRS symptom 
score. In depressed patients, after the 8 weeks treatment, Th1 and Th2 cytokines were 
reduced, though the difference in Th1 was not statistically significant. The Th1/Th2 
ratio was significantly decreased. The plasma TGFβ1 was significantly increased after 8 
weeks treatment with antidepressant medication. The results indicate that Th1, Th2, and 
Th3 are all involved in the depressed state of a subgroup of depressed patients and are 
all corrected by antidepressant treatment. 
 The role of high Th1 and Th2 cytokines in depression has been well documented 
(14-19, 35). It has also been found that antidepressants can decrease the Th1/Th2 or pro-
inflammatory/anti-inflammatory cytokine ratio (20, 36, 37) and it has been hypothesized 
that cytokine hypersecretion may be involved in the pathophysiology of depressive 
disorders (38). The neurodegenerative hypothesis of depression has been proposed as a 
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result of the imbalance between pro-inflammatory and anti-inflammatory cytokines that 
leads to production of a high concentration of the neurodegenerative metabolite, quino-
linic acid, in the brain 39). The impaired balance between Th1 and Th2 cytokines is 
believed to play a role in appropriate modulation of cellular responses in the brain 
during psychological stress and depression (25). Our findings that the Th1 and Th2 
cytokine levels and the Th1/Th2 ratio in patients were higher than in normal controls are 
in agreement with the previous findings. 
 In the present study, a significant change in the Th1 cytokine, IFN-γ was not de-
tected. This could be due to the difference in methodology used and the gender differ-
ence. In the previous studies, stimulated whole blood was used to analyze cytokine 
concentrations whereas plasma samples were used in the present study. Regarding the 
gender issue, almost all previous studies were carried out in male patients. In our study 
also, all male patients showed reduction in IFN-γ after treatment. However, those 
female patients of reproductive age showed increase in IFN-γ levels after treatment. The 
gender difference in inflammatory response in different illness conditions (40, 41) had 
been reported. Moreover, it was reported in an epidemiological study that age and 
gender significantly affected on plasma cytokine levels in depressed and schizophrenic 
patients (42). Nevertheless, we found a significant decreased in Th1/Th2 ratios follow-
ing antidepressant treatment. Therefore, our finding also is in agreement with the 
hypothesis that the balance in the Th1 and Th2 cytokines could be important in the 
pathophysiology of depression. 
 In plasma samples, the Th3 cytokine, TGFβ1, showed lower value in depressed 
patients before treatment and the Th1/Th3 ratio was significantly higher in the de-
pressed patients. Moreover, plasma Th3 levels were significantly and inversely corre-
lated with the HDRS depression scale of the patients and were increased after treatment. 
It has been documented that increased TGFβ1 production correlates with the resolution 
of inflammatory responses, particularly in organ specific autoimmune diseases (29). 
TGFβ1 was proposed to play an important role in maintaining tolerance in immunologi-
cally privileged sites including the central nervous system. These findings explain the 
significant increase in the Th3 cytokine after antidepressant therapy in our patients, the 
change being associated with the decrease in the Th1/Th2 ratio. It has been reported that 
TGFβ1 promotes Th2 differentiation, which leads to increased IL4 production and 
decreased IFNγ synthesis (43). In the present study, although both Th1 and Th2 cyto-
kine levels reduced after treatment, the Th1/Th2 values also reduced. This could indi-
cate a shift in the cytokine balance towards the Th2 side. Thus, not only the balance 
between Th1 and Th2 cytokines, but also the increase in the Th3 cytokine plays a 
significant role in the pathophysiology of depression and antidepressants were shown to 
change the Th1/Th2 balance at least in a subgroup of patients. 
 This study has some limitations. Since we collected the plasma samples only in the 
beginning and at the end of 8 week therapy, some significant changes in cytokine levels 
could have been missed. Moreover, if we had also measured the cytokine levels in basal 
and stimulated whole blood culture supernatants, we might have obtained a more 
comprehensive view regarding the changes. Future studies will attempt to assess these 
possibilities. 
 In conclusion, the result of this study showed the importance of the Th3 cytokine, 
TGFβ1, in the psychoimmunology of depressed patients. The antidepressants seem to 
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react through the regulatory effect of TGFβ1 on the Th1 and Th2 balance, with a shift 
towards the latter.  
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Abstract 
Background: Treatment with pro-inflammatory cytokine, IFNα was documented to 
result in neuropsychiatric complications including depression and treatment with anti-
depressant, paroxetine could improve the depressive symptoms. Therefore, the effects 
of IFNα on behaviour and cytokine changes in the whole blood culture and in the 
prefrontal cortex, hypothalamus and hippocampus areas of the brain in Wistar rats were 
investigated with emphasis on the role of paroxetine in the prevention of depressive 
behaviour induced by pro-inflammatory cytokines.  
Method: The group of rats treated with IFNα (s.c. 50,000 IU/kg for 3 days/week for 5 
weeks) was compared with 3 other groups; (1) saline control (s.c normal saline 0.2 
ml/kg/day for 7 weeks) group, (2) paroxetine control group (Paroxetine suspension 
orally 10 mg/kg/day for 7 weeks) and (3) group treated with paroxetine for 2 weeks 
followed by IFNα for 5 weeks.  
Result: In open-filed, the IFNα treated rats showed anxiety behaviour compared to the 
rats from the other groups. There was no significant difference in home cage emergence 
test, Morris water maze and object recognition test. There is no significant difference in 
plasma corticosterone between groups. The pro-inflammatory cytokines (TNFα, IL1β 
and IFNγ), were significantly higher whereas the anti-inflammatory cytokine, IL10 was 
lower in the stimulated whole blood culture of IFNα treated rats. In the brain, both pro-
inflammatory cytokine IL1β and anti-inflammatory cytokine IL10 were higher in 
hypothalamus of the IFNα treated rats; by contrast the concentration of IL10 was lowest 
in hippocampus region of this group compared to the other groups. The paroxetine pre-
treated rats did not show these cytokine changes following IFNα treatment.  
Conclusion: Thus it appears that paroxetine pre-treatment prevents the pro-
inflammatory changes in blood and brain following IFNα treatment in turn prevents the 
anxiety behaviour. 
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Introduction 
Interferon-α (IFNα) is used for the treatment of chronic viral diseases such as chronic 
hepatitis B and C and for the treatment of different malignancies (1). The duration of 
treatment varies from months, in the case of hepatitis, to years, in certain types of 
malignancies and the therapy may induce different side effects. Following chronic 
treatments, there are more severe side effects involving the immune system and the 
brain (2, 3). In short term applications of high doses of IFNα given intravenously or 
intracerebroventricularly, 20 to 60 percent of patients developed organic mental disor-
ders after short latency of several days but symptoms generally subside promptly after 
cessation of treatment (4-11). However, it was reported that moderate deficits in cogni-
tive function occassionally persisted even after cessation of therapy (12). Compared to 
the side effects occurring in high-dose therapy, neuropsychiatric effects during low-dose 
therapy are reported to be less severe and occur after a longer latency in 4 to 16 percent 
of patients (13). 
 It is widely accepted that major depression is accompanied by disturbances in the 
serotonin (5-HT) metabolism (14-16). IFNα up-regulates the transcription of the central 
5-HT transporter, which increases the reuptake of 5-HT and thereby reduces the ex-
tracellular 5-HT concentration (17). It was also reported that IFNα increases the binding 
at low affinity 5-HT1A receptor sites that might induce the psychiatric symptoms of 
depression and anxiety (18). In addition, the IFNα induced protein (15-kDa protein), 
stimulates IFNγ synthesis (19) and thus activates the enzyme indolamine 2-3, dioxy-
genase (IDO) which catabolises tryptophan to kynurenine (20), which is again catabo-
lised into neurodegenerative quinolinic acid and neuroprotective kynurenic acid and the 
chronic imbalance in those two metabolites could lead to depression (21). It is also 
proposed that IFNα may induce depression through activation of the HPA system and 
an increased synthesis of IL1β (22). Tryptophan depletion and a reduction in serotonin 
synthesis following the cytokine induced induction of IDO also contribute to pathology 
of depression (23). 
 Antidepressants have been shown to correct the imbalances between pro- and anti-
inflammatory cytokines or T-helper 1 (Th1) and T-helper 2 (Th2) cytokines in both 
animal and human studies (24, 25). In addition, the T-helper 3 (Th3) cytokine, trans-
forming growth factor (TGF) β1, regulates the balance between the pro- and anti-
inflammatory cytokines in depressed patients after treatment with antidepressants (25). 
There is evidence that paroxetine is an effective SSRI antidepressant in the treatment 
(26, 27) and prevention (28, 29) of IFNα-induced depressive illness. However, the role 
of paroxetine in correcting the changes in behaviour and dysfunctional brain and blood 
immune system changes in rats has not been previously reported. It is hypothesized that 
paroxetine may prevent the changes in behavioural untoward effects caused by chronic 
parenteral administration of IFNα by decreasing the proinflammatory changes and 
thereby limiting the adverse effects on the serotonin system. 
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Materials and Methods 
Animals 
Male Wistar rats from Charles River Laboratory weighing 250-300gm were housed 
individually in standard Makrolon cage and kept under 12-hour reversed light-dirk cycle 
with food (standard diet, Charles River) and water ad libitum. The study was approved 
by the institutional ethical committee for animal experimentation, University of Maas-
tricht, The Netherlands. 
Treatment 
The rats were assigned to 4 different treatment groups of 10 rats each as followed 
(Table 1). 
Table. 1. Table showing the different treatment groups of animals 
Group Treatment (N=10/group) 
Control Saline (s.c) 0.2 ml/kg everyday for 47 days 
IFNα Saline (s.c) 0.2 ml/kg everyday for 14 days followed by IFNα s.c (Interon A, Schering 
Plough) 50,000 IU/kg for 3 days/week for 5 weeks 
P + IFNα Paroxetine suspension (Seroxat, GlaxoSmithKline) orally 10 mg/kg for 14 days 
followed by IFNα s.c (Interon A,Schering Plough) 50,000 IU/kg for 3 days/week for 5 
weeks 
P Paroxetine suspension (Seroxat, GlaxoSmithKline) orally 10 mg/kg for 47 days 
 
All injections or medications were given between 13:00 to 14:00 hours daily to avoid 
the effects of handling for administration of medication on behavioural experiment. The 
dose of IFNα was selected on the basis of previous experiments in the published litera-
ture (30-33). The route and frequency of injection of IFNα reflected the clinical situa-
tion. The dose of paroxetine used based on the previous studies by other investigators 
(34, 35). 
Behavioural procedures 
The following behavioural studies were undertaken commencing 7 days after Interon-A 
treatment (i.e. 21 days after the start of the experiment). Randomisation was carried out 
to avoid the confounding effect of time of the day and immediate effect of an injection 
or medication. The body weight was measured once a week. 
Exposure to the open field arena for 5 min. The apparatus consisted of a square Plexi-
glas base (100 cm x 100 cm) with a black floor and 40 cm high transparent Plexiglas 
walls (36). The arena was arbitrarily divided into 4 corners, 4 walls and centre. A 
camera was placed 250 cm above the centre of the open field. After the rat was placed 
in the centre of the arena, the distance moved and the velocity of movement of the rat 
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were tracked automatically with a computerised system (Ethovision, Noldus, The 
Netherlands). Testing was carried out in 5 min session per day for four days. 
Object recognition test. The object recognition test was performed as described else-
where (37). The apparatus consisted of a circular arena, 83 cm in diameter. Half of the 
40 cm high wall was made of grey polyvinyl chloride, the other half of transparent 
polyvinyl chloride. The light intensity was equal in the different parts of the apparatus. 
Two objects are placed in a symmetrical position about 10 cm away from the grey wall. 
Four different sets of objects used were: 1) a cone consisting of a grey polyvinyl chlo-
ride base (maximal diameter 18 cm) with a collar on top made of brass (total height 16 
cm), 2) a standard 1 l transparent glass bottle (diameter 10 cm, height 22 cm) filled with 
sand, 3) a metal cube (10.0 × 5.0 × 7.5 cm) with two holes (diameter 1.9 cm), and 4) an 
aluminium cube with a tapering top (13.0 × 8.0 × 8.0 cm). The objects were heavy 
enough to prevent from being displaced by the rats. 
 In the first week, the animals were handled daily and were adapted to the procedure 
for the first two days; the rats were allowed to explore the apparatus in the absence of 
any objects twice for 3 min each day. In the following 2 weeks the rats were adapted to 
the testing procedure until they showed a stable discrimination performance, i.e., the 
rats could recognise the old object at a 1-h interval after the exposure to the objects but 
could not recognise after 24 hours. 
 A testing session comprised two trials. The duration of each trial was 3 min. During 
the first trial (T1) the apparatus contains two identical objects (samples). A rat was 
always placed in the centre of the transparent front segment of the apparatus facing the 
wall. After the first exploration period the rat was put back in its home cage. Subse-
quently, after a 1-hour interval, the rat was put back in the apparatus for the second trial 
(T2), but in this occasion with two dissimilar objects, a familiar one (the sample) and a 
new one. The times spent exploring each object during T1 and T2 was recorded manu-
ally by means of a personal computer. A third trial (T3) was undertaken 24 hours later 
with two dissimilar (one old and one new) objects. To avoid interference there is always 
one day without testing between T3 of first testing and T1 of next testing. 
Behaviour in Morris water maze: Morris water maze test was performed using a black 
water tank (diameter 1,53m) (38). The escape platform (diameter 11cm) was submerged 
(1,5cm) below the surface of the water. The water temperature was 22°C. The water 
was not made opaque, because the escape platform was black and hence virtually 
invisible in the black tank. The water tank was divided into four quadrants designated 
(training, right adjacent, left adjacent and opposite) relative to the position of the escape 
platform. Abundant spatial cues were provided by the furniture in the room. A video 
camera, mounted in the centre above the circular pool, enabled all the movements in 
terms of distance, velocity and location of a rat to be tracked automatically (Ethovision, 
Noldus equipment) and the results stored on a personal computer. 
 At the beginning of the experiment, the rat was placed in the tank from four differ-
ent randomly chosen start positions, and trained to find the invisible platform at a fixed 
position in the water tank. A trial lasted until the rat has located the platform or until 60s 
had elapsed. If a rat could not find the platform within 60s, it was placed on the plat-
form for 3s and then removed from the water tank. On the first day, the rats were 
subjected to four trials. On the 3 subsequent days the rats were given 8 trials per day. 
The time between each trial was 10 mins. A probe trial lasting 60s, during which the 
platform was removed from the water tank, was given after the last trial. In the probe 
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trial the rats were placed in the tank facing the wall of the tank from the position oppo-
site to the quadrant in which the platform was removed (38). 
Home Cage Emergence Test. The home cage emergence test was applied once a week 
throughout the experimental period. In this test, the cage which contains the rat that 
housed in it was placed in the middle of the open field (39). The cage top was left open 
so that the rat could emerge via an easily accessible grid. The latency (in seconds) to 
emerge from the home cage (i.e., the time taken until a rat was on the grid outside its 
cage with all four legs) was scored. 
Biochemical analyses 
Sample collection. One week after cessation of behavioural experiment and drug treat-
ments, the rats were euthanized with thiopentone (150mg/kg i.p). The blood was col-
lected from the aorta in heparinised tubes within 3 to 5 minutes after the rats had been 
anaesthetised with thiopentone. The procedure was taken out between 09:00 to 10:00 
hours in the morning. One ml of whole blood was taken for the whole blood stimulation 
culture and the remainder was centrifuged and plasma was collected and stored at -70ºC 
for corticosterone analysis. 
 Immediately after blood collection, the rats were decapitated and three brain areas 
(hippocampus, hypothalamus and pre-frontal cortex) were dissected on a frosted glass 
plate and put in sterile chilled PBS (pH7.4-7.6) containing protease inhibitor cocktail 
(Roche) and stored at -70ºC for analysis of cytokines at a later date. 
Serum corticosterone analysis. Plasma corticosterone was analysed using EIA kit for rat 
and mouse corticosterone from IDS. The detection limit was 18 ng/ml and the intra-
assay coefficient of variation was 3.1%. 
Blood culture and cytokine analysis. The pro-inflammatory IL1β, TNFα, IFNγ and anti-
inflammatory IL10 and TGFβ1 cytokines were analysed in both supernatants from 
stimulated and unstimulated cultures. The whole blood was collected at room tempera-
ture to prepare cultures. Whole blood was cultured in 24-well Costar plate and for each 
rat, 2 stimulated culture wells and 2 unstimulated culture wells were prepared. In each 
well 250μl of whole blood was incubated at 37°C for 48 hours with 750μl of RPMI 
1640 medium containing 50μg/ml LPS (Sigma) and 10μg/ml Concanavalin A (Sigma) 
for the stimulated cultures (40). The RPMI 1640 without mitogens was used for un-
stimulated culture. The supernatants were collected after 48-hour incubation and kept at 
-70ºC for the analysis of cytokines at a later date. The blood cytokines were analysed in 
duplicate using ELISA developed with DuoSet ELISA from R&D System, UK for rat 
IL1β, TNFα, IFNγ and IL10 and TGFβ1 according to the instructions of the manufac-
turer. The detection limits were 39.06pg/ml for IFNγ and 62.5pg/ml for the other cyto-
kines. The intra-assay coefficients of variation were: 3.2% for rat IL1β, 3.5% for rat 
TNFα, 5.6% for rat IFNγ, 5.2% for rat IL10 and 3.8% for TGFβ1, respectively. 
Brain cytokine analysis. Brain cytokine analysis was done with the minor modification 
on the previously published methods (41, 42). Brain samples were thawed in an ice bath 
and sonicated for 20 seconds in cold sterile PBS (pH7.4-7.6) with protease inhibitor 
cocktail (Roche). The protein concentration was analysed by Lowry’s method on 
sonicated samples (43, 44). The sonicated samples were centrifuged and the brain IL1β, 
TNFα, and IL10 were analysed in duplicate in the supernatant diluted with sterile PBS. 
The brain cytokine levels were analysed in duplicate using ELISA developed with 
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DuoSet ELISA from R&D System, UK for rat IL1β, TNFα, IFNγ and IL10 and the 
concentrations were expressed as pg/g protein. The detection limit for all cytokines was 
62.5pg/ml. The intra-assay coefficients of variation were: 3.2% for rat IL1β, 3.5% for 
rat TNFα, and 5.2% for rat IL10, respectively. 
Data analysis 
The effect of treatment on behaviour and immune parameters were analysed using two-
way ANOVA and Bonferroni or Scheffe post-hoc tests were used to perform the pair-
wise comparison. To determine the significant difference between the 4 groups for the 
data with high standard deviation, non-parametric Kruskal Wallis test was used. The 
analysis was carried out using SPSS version 11.5 and the probability of 0.05 or below 
was considered to be statistically significant. 
Results 
Behaviour 
In the open-field test the effect of interaction between IFNα treatment and paroxetine 
treatment showed significant effect on mean distance moved (F=1.158, p=0.043), 
velocity of movement in the open field (F=4.632, p=0.041) and time spent in the corner 
(F=5.658, p=0.025) (Table-2). 
 The post-hoc Bonferroni test showed significant difference between saline control 
and IFNα treated group or paroxetine group in time spent in the corner (p=0.031 and 
0.038 respectively). The IFNα treated group also showed difference in mean distance 
moved (p=0.041), and mean velocity of movement (p=0.047) in open field compared to 
saline controls. 
 However, no effects of IFNα treatment, paroxetine treatment and interaction were 
observed on home cage emergence test, Morris water maze test and object recognition 
test.  
Table-2—Descriptive data on behaviour in open field 
Parameters  Saline IFNα  P+IFNα P 
Mean Distance Moved (m) 
(mean ± S.D)  
0.62±0.23 2.61 ± 1.8 0.84 ± 0.35 1.34 ± 0.69 
Mean Velocity (cm/sec)  
(mean ± S.D)  
6.25 ± 1.06 9.55 ± 1.23 7.94 ± 1.58 8.37 ± 1.14 
Percent time spent in corner 
(%) 
17.39 ± 3.27 35.34 ± 6.77 18.99 ± 4.5 32.58 ± 7.7 
Peripheral corticosterone and cytokines 
The descriptive values of the peripheral corticosterone and cytokines were shown in 
table-3. There was no significant difference in corticosterone concentrations between 
the groups. 
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 Regarding cytokine levels in stimulated and unstimulated whole blood culture 
supernatants, significant differences between all studied groups were shown in IL1β 
concentration in stimulated whole blood culture (χ2=15.901, p=0.001), TNFα concentra-
tion in both unstimulated and stimulated whole blood cultures (χ2=29.715, p=0.000; 
χ2=19.669, p=0.000, respectively), INFγ concentration in unstimulated and stimulated 
whole blood cultures (χ2=12.426, p=0.006; χ2=15.386, p=0.002, respectively), IL10 in 
unstimulated and stimulated whole blood cultures (χ2=8.352, p=0.039; χ2=20.381, 
p=0.000, respectively) and in IFNγ/IL10 ratio (χ2=23.434, p=0.000).  
 
Table-3—Descriptive data on corticosterone concentration in plasma and cytokines concentrations in whole 
blood culture supernatants 
Parameters  Saline IFNα P+IFNα P 
Plasma Corticosterone 
(mmol/l) (mean ± S.D) 
200.64 ± 116.25 228.79 ± 120.45 218.61 ± 125.58 270.26 ± 135.34 
IL1β (pg/l) (mean ± S.D) 
 Unstimulated 
 Stimulated 
 
0.00 
0.00 
 
16.56 ± 12.05 
200.74 ± 75.15 
 
0.00 
3.96 ± 2.30 
 
0.00 
0.00 
TNFα (pgl/l)  
(mean ± S.D) 
 Unstimulated 
 Stimulated 
 
 
664.16 ± 14.51 
1899.9 ± 547.01 
 
 
242.84 ± 40.45 
4582.7 ± 1914.7 
 
 
199.14 ± 32.66 
2491.4 ±1599.1 
 
 
648.69 ± 4.78 
1345.05 ± 291.1 
IFNγ (pg/l) 
(mean ± S.D) 
 Unstimulated 
 Stimulated 
 
 
122.84 ± 80.96 
186.55± 89.32 
 
 
446.97 ± 112.97 
847.14 ± 361.59 
 
 
174.13 ± 46.59 
560.15 ± 187.72 
 
 
435.91 ± 138.31 
950.12 ± 228.43 
IL10 (pg/l) (mean ± S.D) 
 Unstimulated 
 Stimulated 
 
547.48 ± 159.96 
8185.39 ± 779.8 
 
0.00 
3293.75 ± 618.5 
 
194.06 ± 61.3 
6548.17 ± 517.7 
 
62.41 ± 62.41 
4814.0 ± 1401.1 
IFNγ/IL10 
(mean ± S.D) 
 Stimulated 
 
 
0.028 ± 0.014 
 
 
0.804 ± 0.49 
 
 
0.091 ± 0.038 
 
 
0.213 ± 0.137 
TGFβ1  (μg/l) 
(mean ± S.D) 
 Unstimulated 
 Stimulated 
 
 
3.15 ± 0.14 
4.35 ± 0.24 
 
 
3.55 ± 0.25 
4.68 ± 0.14 
 
 
3.01 ± 0.12 
4.15 ± 0.2 
 
 
3.05 ± 0.18 
4.25 ± 0.34 
  
 The IFNα treatment showed significant effects on (1) IL1β concentration in stimu-
lated culture (F=6.125, p=0.019), (2) TNFα concentrations in stimulated and unstimu-
lated cultures (F=18.45, p=0.000 and F=2143.55, p=0.000, respectively), and (3) IL10 
concentration in stimulated culture (F=5.941, p=0.020). 
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 The interaction between IFNα treatment and paroxetine treatment showed signifi-
cant effects on (1) IL1 concentration in stimulated culture (F=5.66, p=0.023), and (2) 
IL10 concentration in stimulated culture (F=26.158, p=0.000). 
 The post-hoc Scheffe test showed significant difference between IFNα treated 
group and all other groups (saline control, paroxetine+ IFNα, and paroxetine alone) in 
mitogen stimulated peripheral IL1 production (p=0.013, 0.011 and 0.024 respectively), 
basal peripheral TNFα production (p=0.016, 0.000 and 0.000 respectively), and mitogen 
stimulated peripheral TNFα production (p=0.015, 0.001 and 0.000). The post-hoc 
Scheffe test also showed significant difference between IFNα treated group and saline 
control group or paroxetine+ IFNα group in mitogen stimulated peripheral IL10 produc-
tion (p=0.008 and 0.000 respectively). The post-hoc Bonferroni test showed significant 
difference between IFNα treated group and saline control group or paroxetine+ IFNα 
group in IFNγ/IL10 production ratio (p=0.004 and 0.000 respectively). The TGFβ1 
concentrations showed no significant difference between the groups. 
Brain cytokines 
Table-4—Descriptive data on cytokines concentrations in different brain regions 
Parameters  Saline IFN  P+IFN
   
P 
IL1( (pg/g) 
(mean ±S.D) 
Hippocampus 
Hypothalamus 
Prefrontal cortex 
 
 
2396.5 ± 555.2 
323.19 ± 124.47 
107.78 ± 22.19 
 
 
2345.8 ± 724.5 
884.95 ± 277.9 
143.77 ± 28.62 
 
 
1814.6 ± 653.9 
414.98 ± 115.89 
118.77 ± 10.27 
 
 
2358.0 ± 784.9 
290.62 ± 73.09 
120.47 ± 41.07 
 
TNFα (pgl/g) 
(mean ± S.D) 
Hippocampus 
Hypothalamus 
Prefrontal cortex 
 
 
5477.1 ± 1326.3 
22295.8± 8212 
4946.2 ± 1621.2 
 
 
 
4766.6 ± 1645.1 
22008.2 ± 6437.2 
5557.2 ± 2127.3 
 
 
4231.6 ± 1413.9 
22160.1±8222.4 
5345.7 ± 1415.1 
 
 
5807.6 ± 2232.2 
19682.9±6853.7 
5607.4 ±1674.2 
IL10 (pg/g) 
(mean ± S.D) 
Hippocampus 
Hypothalamus 
Prefrontal cortex 
 
 
11083.1± 2636 
22482.8±7959.2 
5772.6 ± 2309.2 
 
 
 
7899.2 ± 2253.4 
54228.6±14269.9 
7148.1 ± 1453.3  
 
 
8256.4 ± 2859.6 
26226.7± 7246 
6163.8 ± 822.9 
 
 
9176.1 ± 2635.4 
20463.3± 7474 
6980.4 ± 1617.7 
 
The descriptive values of the brain cytokines were shown in table-4. 
 Regarding cytokine levels in brain, significant differences between all studied 
groups were shown in IL1β concentration (χ2=23.03, p=0.000) and IL10 concentration 
(χ2=21.535, p=0.000) in hypothalamus. 
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 The IFNα treatment showed significant effects on (1) IL10 concentration in hippo-
campus (F=9.362, p=0.005, respectively), and (2) IL1β and IL10 concentrations in 
hypothalamus (F=35.162, p=0.000 and F=33.525, p=0.000, respectively). 
The interaction between IFNα treatment and paroxetine treatment showed significant 
effects also on IL1β concentration and IL10 concentration in hypothalamus (F=15.785, 
p=0.000 and F=17.415, p=0.000, respectively). 
 The post-hoc Bonferroni test showed the significant difference in IL10 concentra-
tion in hippocampus between IFNα treated group and saline control group (p=0.002). 
The post-hoc Scheffe test showed significant difference between IFNα treated group 
and all other groups (saline control, paroxetine+ IFNα, and paroxetine alone) in IL1β 
concentration in hypothalamus (p=0.000, 0.000 and 0.001 respectively), and IL10 
concentration in hypothalamus (p=0.000 for all compared groups).  
 
Discussion 
The IFNα rats treated with IFNα 50,000 IU/kg s.c for three days a week for 5 weeks 
showed anxiety behaviour in open field. The increased anxiety in open field is one of 
the depressive behaviours especially induced by LPS which stimulate the pro-
inflammatory cytokine secretion (45). This explained the finding in our study in which 
the pro-inflammatory cytokine IFNα induced sickness behaviour which is equivalent to 
human depressive behaviour. The previous rodent studies also showed depressive like 
behaviour such as social anhedonia in sucrose preference test (32) or increased immo-
bility in the forced swimming test (31) in IFNα-treated rats. However, in our study, 
there was no difference in home cage emergence test, object recognition test and Morris 
water maze test. The behavioural results of our study indicated that IFNα injection can 
induce anxiety behaviour in open field but does not cause cognitive impairment. The 
effect of IFNα on cognitive function is still controversial. Though there appears to be 
little information available on the effect of IFNα on cognitive function in rats, a recent 
human study revealed no effect of IFNα on cognitive function after 6 month treatment 
in chronic hepatitis-C patients (46) whereas other investigator showed that the cogni-
tive-depressive symptom score increased at 8th week of IFNα therapy (47). 
 The most pronounced changes in the cytokines were detected in the IFNα group. In 
the peripheral blood culture, IFNα appeared to suppress the basal TNFα secretion but 
enhance the response to mitogen stimulation. Our results also showed that IFNα en-
hanced the production of IL1β in both basal and stimulated peripheral blood. There is 
very limited literature available on the cytokines response in IFNα treatment in rats 
though one study on effect of IFNα on rat kupffer cells showed increased TNFα produc-
tion but not on IL1β whereas another showed no effect of IFNα on plasma TNFα and 
IL6 (30). However, in a clinical study on changes in TNFα production during IFNα 
therapy, it was shown that the stimulated production of TNFα was significantly in-
creased in those responding to the treatment (48). The paroxetine pre-treatment, in our 
study, significantly prevented the increase peripheral IL1β but not TNFα production by 
IFNα. 
 Regarding the Th2 or anti-inflammatory cytokine IL10 production, our finding 
showed that mitogen stimulated IL10 production was significantly lower in IFNα group 
and IFNγ/IL10 (Th1/Th2) was significantly higher also in this group. This is the first 
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study in which the effect of IFNα on peripheral IL10 response was reported in rodents 
though there is clinical evidence that IL10 production declined with IFNα treatment (49, 
50) in those who responding to the treatment. The paroxetine pre-treatment again 
prevented the decreased IL10 production in peripheral blood culture in our study. Taken 
together, the anxiety behaviour in IFNα treated rats in open field might be associated 
with the pro- versus anti-inflammatory cytokines imbalance in the blood since such an 
imbalance was well documented in clinical depression (25). However, those behavioural 
and immune changes were prevented by paroxetine pre-treatment. Unfortunately, this 
study failed to demonstrate the change in the Th3 cytokine, TGFβ1 which regulates the 
Th1 and Th2 balance by suppressing the Th1 cytokines like IFNγ and TNFα (51, 52), 
despite the beneficial effect of paroxetine that prevented the imbalance in Th1 versus 
Th2 or pro- versus anti-inflammatory cytokines.  
 In contrast to the changes in the blood, in the brain, IFNα induced decrease in IL10 
(anti-inflammatory) cytokines in hippocampus whereas IFNα increased both IL1β (pro-
inflammatory) and IL10 in hypothalamus. There was indeed immune activation in 
hypothalamus region of the brain in IFNα treated rats indicated by both high pro- and 
anti-inflammatory cytokines. That finding also indirectly indicated the minor change in 
pro- versus anti-inflammatory cytokines imbalance by decreasing the anti-inflammatory 
part in the hippocampus area of the brain in IFNα treated rats. However, there is no 
significant change in IL1β in the hippocampus. This finding is in agreement with the 
finding of the study by De La Garza and group (30) in which the IFNα treatment 
showed no effect on mRNA expression of IL1β and IL6 in the hippocampus of the 
Wistar rats. There was also no significant effect of both IFNα and paroxetine alone or in 
combination on TNFα concentrations in these three brain regions. This finding was in 
agreement with that of Gayle and group (53) which demonstrated that IFNα has no 
effect on TNFα mRNA expression. Nevertheless in the present study paroxetine pre-
treatment resulted in reduction of both IL1β and IL10 in hypothalamus. 
 Though we could demonstrate the changes in cytokines in both periphery and in the 
hypothalamus, we failed to demonstrate a change in the plasma corticosterone concen-
tration. This was surprising as IL1β is considered to be a potent activator of the HPA 
axis. However, there was also high IL10 in hypothalamus which indicated the possibil-
ity of balancing the pro-inflammatory cytokine IL1β action by anti-inflammatory 
cytokine IL10. The lack of change in corticosterone might also be partly due to the 
disturbance in the system by anaesthetic injection before sample collection. 
Taking altogether, these findings indicated that the brain cytokine changes may occur 
independently of the peripheral blood and also differ between the different brain regions. 
Nevertheless, both blood and brain cytokines indicated that there is inflammatory 
hyperactivity in IFNα treated rats that coincides with the increased anxiety in the open 
field. 
 In conclusion, this study has supported the clinical observation that the negative 
effects of IFNα on behaviour and blood and brain cytokine changes are largely pre-
vented by chronic paroxetine pre-treatment. This suggests that SSRIs may prevent the 
immune system hyperactivity caused by IFNα treatment in both blood and brain and 
thereby prevents the depressive like changes shown in patients. 
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Abstract 
Background: The interferon-α (IFNα), a cytokine used to treat the chronic viral infec-
tions and certain cancers can induce depression in some patients and part of them get 
persistent moderate cognitive deficit. This cytokine enhances the tryptophan breakdown 
and kynurenine metabolism. This leads to an increase in neurotoxic metabolites such as 
quinolinic acid which can induce apoptosis of astrocytes. The increase in astrocyte 
apoptosis in hippocampus may be a prelude to the onset of depression. The purpose of 
this study was to examine the impact of chronic IFNα on density of astrocytes and 
microglia in the rat hippocampus. As the selective serotonin reuptake inhibitor (SSRI), 
fluoxetine attenuates the symptoms of depression the effect of fluoxetine pre-treatment 
on effect of chronic IFNα was also investigated. 
Method: To test the above hypothesis, 4 groups of 6 male Wistar rats were assigned 
into (1) saline control group, (2) fluoxetine (F) group, (3) interferon-α group and (4) F + 
interferon-α group. After 7 weeks of above treatment, animals were processed for 
immunohistochemistry of glial fibrillary acid protein (GFAP) and tomato-lectin to 
detect the astrocyte and microglial densities respectively. The sections were quantified 
with image analysis system in hippocampal dentate gyrus and CA3 region. 
Result: The astrocyte density was significantly reduced in both interferon-α treated 
group and SSRI+ interferon-α group in dentate gyrus whereas the additional reduction 
was observed only in interferon-α treated group in CA3 region. The microglial activity 
showed no difference between the groups. 
Conclusion: INF-α treatment reduced the density of astrocytes in the hippocampus 
especially in the DG and CA3 region without effect on the density of microglia. Chronic 
fluoxetine pre-treatment did not fully prevent the changes in astrocytes density. These 
results suggest that the decrease of astrocytes density by IFNα may contribute to the 
depressive episodes with persistent cognitive deficit seen in some patients treated with 
IFNα. 
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Introduction 
Interferon-α (IFNα) is a cytokine used for the treatment of chronic viral diseases such as 
chronic hepatitis B and C and for the treatment of different malignancies (1). Following 
chronic treatments, there are severe side effects involving the immune system and the 
brain (2, 3). In short term applications of high doses of IFNα, 20 to 60 percent of pa-
tients, after short latency of several days, developed organic psychosis and severe 
depression which generally subsided promptly after cessation of treatment (4-11) 
though moderate deficits in cognitive function occasionally persisted even after cessa-
tion of therapy (12). Less severe neuropsychiatric side effects such as mild depression 
was reported to occur after a longer latency in 4 to 16 percent of patients treated with 
low-dose IFNα (13). Since in IFNα treatment, 10-20% of discontinuation of treatment is 
due to neuropsychiatric side effects, there is a growing interest for a better understand-
ing of possible underlying mechanisms (13). 
 The human IFNα induced protein (15-kDa protein) that stimulates IFNγ synthesis 
(14). As a consequence the enzyme indolamine 2-3, dioxygenase (IDO) was induced 
and this catabolises tryptophan to kynurenine and its metabolites through the 
kynurenine pathway (15). There is evidence that the resulting reduction in the availabil-
ity of tryptophan for serotonin synthesis contributes to the depressed state seen in 
patients treated with IFNα (16). Kynurenine is further catabolised into 3-hydroxy 
kynurenine (3OHK) and quinolinic acid (QA) (17, 18). However, kynurenine is also 
catabolised into kynurenic acid (KA) (19) that could counteract the action of QA (20, 
21). The imbalance between the above QA and KA metabolites was hypothesised to 
play a role in pathophysiology of major depression (22, 23) and in patients treated with 
IFNα (16). 
 In the brain, the tryptophan catabolism through IDO activity takes place in astro-
cytes and microglia (24-27). When IFNα stimulates the activity of IDO, the kynurenine 
metabolism is also enhanced and the high QA and KA will be produced. The high QA is 
proven to be apoptotic specifically to astrocytes (28). 
 In experimental study it has been shown that chronic stress causes a decrease in 
glial fibrillary acidic protein (GFAP) immunoreactive astrocytes in the hippocampal 
formation (29). This effect was partly ameliorated by SSRI fluoxetine. Astrocytes are 
known to synthesise a number of neurotrophic factors that are involved in maintenance 
of neuroplasticity (30, 31). Moreover, they play important role in glutamatergic system 
(32). In addition, astrocytes, unlike microglia, are protective against neurotoxic quino-
linic acid (20, 33-35). Thus, reduction in astrocyte number or function that leads to 
impaired protection would be anticipated to enhance the neurotoxic impact (23). 
 In our previous experimental study, it was demonstrated that chronic IFN-α treat-
ment in rats could induce sickness behaviour and increased in pro-inflammatory cyto-
kines in the blood and the brain and all these effects were prevented by paroxetine pre-
treatment (36) that indicated the preventive effect on immune changes in both blood and 
the brain. 
 The purpose of this study was to test the hypothesis that parenteral administration 
of IFN-α causes reduction in density of astrocytes in the rat hippocampus. The possible 
neuroprotective effect of fluoxetine pre-treatment was also investigated. 
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Materials and methods 
Animals 
Twenty-four male Wistar-rats (Charles River Nederland, Maastricht, The Netherlands) 
of 320 to 360 grams were divided in four groups of six animals. Animals were housed 
in single in standard Makrolon cages and fed with standard rat chow (Charles River 
Nederland, Maastricht, The Netherlands) and drinking water ed lib. The first group was 
the control group, in which animals were treated with subcutaneous injection of normal 
saline 1ml/day, 3 days/week for 7 weeks. The second group was treated with fluoxetine 
(F) 10mg/day (orally) for 2 weeks followed by normal saline injection 1ml/day, 3 
days/week for 5 weeks. The rats of the third group were treated with normal saline 
injection 1ml/day, 3 days/week for 2 weeks followed by subcutaneous injection of 
interferon-α (INF-α) (Interon A, Schering-Plough B.V., Utrecht, The Netherlands) 5000 
IU/kg/day, 3 days/week for 5 weeks. The last group was treated with fluoxetine (F) 10 
mg/kg (orally) for 2 weeks followed by INF-α injection 5000 IU/kg/day for 3 days/week 
for 5 weeks. 
 The oral fluoxetine was given in the small bottle of drinking water in which the 
medicine was dissolved and completion of the intake of daily dose was checked every-
day. The injections were given in the morning between 9 to 10 am by the same technical 
assistant in the order of the rats by systematic randomization to avoid the variability.  
Immunohistochemistry 
Preparation of tissue 
The rats were euthanized with a pentobarbitone sodium injection (150 mg/kg), intraperi-
toneally. The rats were perfused with Tyrode and afterwards with Somogyi fixative (37) 
consisting of 4% depolymerised paraformaldehyde (Merck KGaA, Darmstadt, Ger-
many), 0.05% gluteraldehyde (Merck KGaA, Darmstadt, Germany) and 15% picric acid 
(Fluka Chemie GmbH, Deisenhoten, Germany) in 0.1M PBS (pH7.4). The brain was 
dissected out and postfixated with the same fixative for 2 hours. After that the brain was 
immersed in PBS with 15% sucrose overnight and was frozen using CO2 gas. The 
frozen brains were kept in -80°C and then cut into 30μM sections using the cryostat 
(Leica CM 3050, Leica Microsystem, Heidelberg, Germany). 
Immunohistochemical procedure 
To detect the astrocytes density, GFAP staining was used. For the GFAP-staining 
(G3893, Sigma-Aldrich Chemie GmbH, Munich, Germany), again free-floating hippo-
campal sections were used. The sections were washed 3 times for 10 minutes with TBS-
T, TBS and TBS-T, respectively. The first antibody (GFAP) was diluted 1:1600 times in 
TBS-T. After incubating with the first antibody on the shaker overnight in the cold 
room (4°C), the sections were rinsed for 3 times. After that, the second antibody, 
donkey anti-mouse alexa (488 nm) antibody (Jackson ImmunoResearch Europe Ltd,, 
Cambridgeshire, UK), diluted 1:100 times in TBS-T was added and incubated for an 
hour and a half at room temperature on the shaker. The sections were rinsed 3 times 
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with TBS. After that the sections were mounted on gelatine-coated glasses (0,5% 
gelatine + 0,05% potassium) and closed in with 80% glycerol and glass cover slips. 
 To detect the microglia density, tomato-lectin staining was used. For the tomato-
lectin (B-1175, Vector Labs, Peterborough, England) staining, free-floating hippocam-
pal sections were used. The sections were rinsed 3 times for 5 minutes with TBS, and 
then were incubated with the tomato-lectin glycoprotein for 2 hours at room temperature 
on the shaker. The tomato-lectin was diluted 2000 times in TBS-T. After incubation, the 
sections were again rinsed 3 times for 5 minutes with TBS. Streptavidin alexa (488 nm) 
was added to the sections at a dilution of 1 to 2000 in TBS-T. This had to incubate for 
an hour and a half, again at room temperature and on the shaker. After 3 more rinsing 
steps with TBS, an additional Hoechst-staining (1:500 dilution) was added to visualize 
the nuclei. After the incubation time of 30 minutes sections were rinsed for 3 times 
again with TBS. The free-floating brain sections were then mounted on gelatine-coated 
object glasses (0.5% gelatine + 0,05% potassium) and closed in with 80% glycerol and 
glass cover slips. 
Quantification and data analysis 
From each animal, the photos were taken from three different bregma’s (-3.14, -4.30 
and -5.60 nm) using an Olympus AX 70 microscope equipped with Lympus F-view 
cooled CCD camera. For the epifluorescence detection we used a narrow band pass 
MNIBA filter for Alexa Fluor 488 (from Chroma Technology Corp., Rockingham, 
USA). For the GFAP staining, the photos were taken with 100 times magnification, and 
for tomato-lectine staining, the photos were taken with 400 times magnification. For 
both staining, grey values were analyzed in order to detect the overall density which 
may reflect either number or stromal volume of astrocytes or microglia. For GFAP 
staining, the grey value analysis was performed on dentate gyrus (DG) area and CA3 
area whereas for tomato-lectin staining, only DG area was used. To analyze the grey-
values the software program cell^p (Olympus Nederland B.V., Zoeterwoude, The 
Netherlands) was used. The thresholds for the GFAP analysis were set at 65 (low) and 
200 (high) to get an equal intensity and as less background signal as possible, and for 
the tomato-lectin, the thresholds were set at 802 and 2838. After defining the area of 
interest, the program measures the area (µm2) and the mean grey values. For the tomato-
lectin photos, blood vessels shadows were left out of the area of interest.  
Statistical analysis 
For statistical analysis, one-way ANOVA statistics was used to see whether there was 
difference between the groups for either the DG or the CA3 areas. Afterwards post-hoc 
Bonferroni test was performed to find out the difference between each group. P values < 
0.05 were considered as statistical significance. Statistical analysis was done using 
SPSS version 11.0 (SPSS; Chicago, IL, USA). 
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Results 
Astrocytes density 
The GFAP-staining for astrocytes gave the following photos (Figure 1) when viewed 
with the Olympus AX 70 microscope (100X). 
 The descriptive statistics of the mean grey values for DG areas and CA3 areas were 
shown in figures 2 and 3, respectively. 
 There one-way ANOVA showed significant differences in mean grey values be-
tween the four groups for both the DG area (F-value=17.230; p-value=0.00) and the 
CA3 area (F-value=13.497; p-value=0.00). 
 The post-hoc Bonferroni test showed that the mean grey values of GFAP staining of 
the DG area of the INF-α treated group and fluoxetine followed by INF-α group differed 
significantly from the saline control (p=0.028 and 0.022 respectively). 
 In CA3 area, the post hoc test showed the significant difference only between the 
INF-α treated group and the saline control group (p=0.000). In CA3 area, the fluoxetine 
pre-treatment showed no difference from the saline control though there was a trend 
(p=0.078). 
 
 
Figure 1 Pictures were taken with the Olympus F-view II microscope with magnification 100X. GFAP was 
used together with a donkey anti-mouse alexa (488 nm) to stain the astrocytes. All pictures are of bregma -
3,14 and of the DG area. A) group 1 (control); B) group 2 (fluoxetine); C) group 3 (INF-α); D) group 4 (INF-α 
+ fluoxetine). 
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Figure 2 The mean grey values of the GFAP staining of the DG areas of four different groups. The * indi-
cated the significant difference from the Saline Control group. 
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Figure 3 The mean grey values of the GFAP staining of the CA3 areas of all four different groups. The * 
indicated the significant difference from the Saline Control group. 
 
0
10
20
30
40
50
60
Saline SR IFNa SSRI+IFNS I a
Groups
M
ea
n 
G
re
y 
Va
lu
es *
Saline F     IF α           F+IFNα
 
 67 
CHAPTER 4 
Microglia density 
The descriptive values of the mean grey values of tomato-lectin were given in figure 4. 
One-way ANOVA statistics showed no significant difference in mean grey values for 
tomato-lectin staining that indicates the activity of microglia (F=0.619 and p=0.605). 
 
Figure 4 The mean grey values of the tomato-lectin staining of the DG areas of all four different groups. 
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Discussion 
Astrocyte density 
It is apparent from the mean grey values of GFAP stained sections that, in the DG and 
CA3 regions of the rat hippocampus, treatment with INF-α, either alone or in combina-
tion with fluoxetine pre-treatment, results in a reduction in the density of the astrocytes. 
Other investigators have also reported a reduction in astrocyte density in the hippocam-
pus in experimental study in chronic exposure to stress (29) and in human post-mortem 
study in steroid-treated and depressed patients (38). 
 In the present study, although pre-treatment with fluoxetine did not prevent the 
reduction in astrocytes density in the DG region, there was a slight preventive effect of 
fluoxetine pre-treatment in CA3 region. Czeh and group (29) also demonstrate the 
reversal of chronic stress induced reduction in astrocyte number but not reduction in 
stromal volume with fluoxetine treatment. 
 Since astrocytes regulate the synaptogenesis and synaptic strength and control the 
adult neurogenesis in DG area (39-43). this impaired astrocytes density could have 
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negative impact on glia-neuron connection and neuron-neuron connection (29) and 
impaired hippocampal repair following a neurotoxic assault. 
 These preliminary findings lend credibility to the hypothesis that IFN-α treatment 
causes a decrease in astrocyte density. 
Microglia density 
No significant difference was found in the mean grey values in the hippocampus of the 
tomato-lectin staining between any of the treatment groups. This contrasts with the 
experimental findings of the others who reported that the challenge with a single dose of 
the inflammatory mediator lipopolysaccharide caused an activation of microglia in 
hippocampus (44), an effect that was qualitatively similar to that reported to occur in 
rats after exposure to an acute inescapable shock (45). The differences in the experimen-
tal procedures between the acute and chronic effect of the stressors used may be the 
explanation for the lack of change in the microglia density seen in present study. It is 
possible that the adaptive changes occur following the chronic challenge with IFN-α, an 
initial increase being followed by a return to control values. 
Role of above changes in pathophysiology of INF-α-induced depression 
Like other pro-inflammatory cytokines, INF-α enhances the IDO activity (15) and 
kynurenine-3-hydroxylase which in turn resulted in the increase of neurotoxic metabo-
lite QA that induced apoptosis of astrocytes (28). The increase in the neurodegenerative 
arm of neuroprotection-neurodegeneration challenge in kynurenine pathway, as re-
flected in a reduction in the neuroprotective kynurenic acid plasma concentration in 
INF-α-treated patients with depressive symptoms (16) and in patients with major de-
pression (23) could lead to the damage to the astrocytes in the hippocampus. The 
neuroprotective activity of the astrocytes is attributed to their ability to metabolite 
quinolinic acid (33), through glutamate transporter mechanism (46) and by production 
of extracellular S100B (47) thereby reducing the effect of QA in hippocampus. Thus the 
impaired astrocyte densiity that results from chronic INF-α treatment, increase the 
vulnerability of hippocampal neurones to excitotoxic damage. 
Conclusion 
This investigation suggest that INF-α induces a reduction astrocyte density in the rat 
hippocampus. If a similar mechanism occurs in patients treated with this cytokine, it 
might predispose patients treated with INF-α to depression. The cognitive dysfunction 
seen in some patients might also be a reflection of this hippocampal damage. Chronic 
pre-treatment with fluoxetine did not prevent these changes. 
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Abstract 
Background: The olfactory bulbectomised (OBX) rat model is a chronic model of 
depression in which behavioural and neuro-immuno-endocrine changes are reversed 
only after chronic anti-depressant treatment. The cyclooxygenase 2 (COX-2) inhibitor 
celecoxib has been shown to improve the depressive symptoms in patients with major 
depression. 
Method: The association between blood and brain immunological changes and behav-
ioural changes in chronic treatment with COX-2 inhibitor was explored in the OBX rats 
and their sham operated controls. 
Result: The OBX group showed significantly higher locomotor activity than the other 
groups in the first 5 minutes in the open field. In the home cage emergence test, the 
OBX group showed significantly shorter latency period compared to sham group (z=-
3.192, p=0.001) but there is no difference between the other three groups. In the brain, 
(1) in the hypothalamus, the OBX group had a significantly higher IL1β and IL10 
concentrations than OBX+ celecoxib group (z=-1.89, p=0.05) and in IL10 (z=-1.995, 
p=0.046); and (2) in prefrontal cortex, OBX group showed significantly higher concen-
trations of TNFα (z=-2.205, p=0.028) and IL1β (z=-3.361, p=0.001) than OBX + 
celecoxib group but the OBX group showed a significantly lower concentration of IL10 
(p=-3.361, p=0.001) than that of the OBX + celecoxib group. 
Conclusion: The results of this study supported the potential therapeutic role of COX-2 
inhibitor celecoxib. It is possible that the behavioural changes following the chronic 
administration of celecoxib to the OBX rats are associated with an attenuation of the 
increase in the pro-inflammatory cytokines in the brain. 
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Introduction 
The olfactory bulbectomised (OBX) rat model of depression is one of the well known 
rat models of depression in which all behavioural (1-3), anatomical (4, 5), biochemical 
(3, 6-9), and immunological changes (10-15) were shown to be similar to those ob-
served in major depression. Moreover, those changes were reversed by chronic, but not 
acute, antidepressant treatments (3, 8, 10, 14-18). 
 Studies of the changes in humoral immunity in OBX rat model, demonstrated an 
increased serum interleukin (IL) 1β and prostaglandin (PG)E2 release from the whole 
blood cultures (15, 19), and a suppression of basal anti-inflammatory cytokine IL10 
production (15, 19). It was also reported that the OBX rats showed a more pronounced 
increase of early gene expression of c-fos gene, prostaglandin receptor (EP4), tumour 
necrosis factor-α (TNFα) and corticotrophin releasing factor (CRF) after immuno-
stimulant lipopolysaccharide (LPS) treatment compared to sham operated controls (6, 
12). It was shown that these parameters increased in several brain regions particularly in 
the cortical and limbic regions (6, 12). These changes in serum PGE2, and decrease in 
IL10, in OBX rats were attenuated by in vivo treatment with venlafaxine (20). 
 In major depression, an increase of PGE2 in the saliva, serum and the cerebrospinal 
fluid has been reported (21-23). There was also evidence of an increased in vitro PGE2 
secretion from lymphocytes of depressed patients compared to their controls (24). 
Cyclooxygenase (COX) is the key enzyme involved in prostaglandin synthesis that 
exists in two forms, of which COX-2 is cytokine-inducible and is expressed in inflam-
matory cells and also responsible for PGs produced in inflammation (25-30). The 
possible antidepressant effect of COX-2 inhibitor rofecoxib has already been observed 
in osteoarthritis patients with comorbid depression (31). In a prospective, 6-week, 
double-blind, add-on clinical trial with reboxetine with or without COX-2 inhibitor 
celecoxib has been reported that celecoxib significantly enhanced the antidepressant 
response to reboxetine (32). 
 As the association between behavioural improvement and inflammatory changes in 
blood and brain following COX-2 inhibitor therapy has not been explored, this prelimi-
nary study explored the effect of COX-2 inhibitor celecoxib on behaviour and blood and 
brain cytokine changes in OBX rat model of depression.  
Materials and Methods 
Animals 
Male Sprague-Dawley rats (Charles River Laboratory, The Netherlands) weighing 260-
300gm were housed individually in standard Makrolon cage and kept one week before 
operation under 12-hour reversed light-dirk cycle with food (standard diet, Charles 
River) and water ad libitum. The olfactory bulbectomy operation was done after one 
week adaptation and the rats were returned to their same home cages again after 8 hours 
post-operative observation. The study was approved by the Institutional Ethical Com-
mittee for animal experimentation, University of Maastricht, The Netherlands. 
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Operation procedure 
Surgery was performed according to van Riezen & Leonard (1990) (3). In summary, the 
rats were anesthetized s.c. with ketamine HCl (Nimatek, 60mg/kg) and xylazine HCl 
(Xylazin, 30 mg/kg). The animals were positioned on a heating pad during the surgical 
procedures. Under anaesthesia and aseptic conditions, the scalp was shaved and excised. 
A 2 cm midline incision centred on bregma was made and the surface of the skull was 
cleaned and marked for burr holes at 5 mms anterior to bregma and 2 mm on either side 
of the midline. Two holes were then drilled and the olfactory bulbs were removed by 
suction provided by an aspirator pump. Burr holes were then plugged with absorbable 
hemostatic sponges and the incision was sutured. For sham operation, the same proce-
dure was followed except aspirating olfactory bulbs. After surgery, the animals were 
kept under a close observation for 6 to 8 hours to recover. At the first signs of recovery, 
buprenorphine (Temgesic, 0.03 mg/ml) was injected s.c. to relieve the pain for surgery. 
After recovery, animals were returned to their home cages and allowed to recover for 2 
weeks. 
Treatment 
Table. 1. Table showing the different treatment groups of animals 
Group Treatment (N=8/group) 
OBX Olfactory bulbectomy + normal drinking water 
OBX+C Olfactory bulbectomy + celecoxib (Cerebrex) orally 10mg/kg/day x 2 weeks 
Sham Sham operation + normal drinking water 
Sham +C Sham operation + celecoxib (Cerebrex) orally 10mg/kg/day x 2 weeks 
 
The rats were assigned to 4 different groups of 8 rats each as followed (Table 1). The 
medication of celecoxib (Cerebrex from Pfizer, Korea) was given orally in the small 
bottle of drinking water in which the drink was dissolved. The completeness of intake of 
medication per day was checked everyday. 
Behavioural procedures 
The treatment started at 2 weeks after operation. The rats were handled every day in the 
first week to prevent the unnecessary aggressiveness that can affect the behavioural 
procedures. The following behavioural studies were undertaken commencing 14 days 
after starting the celecoxib treatment. The body weight was recorded once a week. 
Exposure to the open field arena for 20 min. Open Field testing (33) was conducted in a 
square, clear Plexiglas box (100 cm×100 cm×30 cm), with an open top and a dark floor. 
The arena of the open field was subdivided in four equal areas (quadrants), which 
reduced the anxiety component of this OF set-up, as the open space, which is normally 
aversive to rodents, was reduced in this set-up. Four rats could be tested simultaneously. 
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The OF apparatus was placed on the floor of an experimental room. A camera was 
installed 2.5 m above the centre of the field. Rats were randomly assigned a quadrant. 
After the rats were placed in each quadrant, the session started until 20 minutes had 
passed. The movements and positions of the animal were recorded and registered 
automatically by a computerized system (EthoVision Color Pro, Noldus, The Nether-
lands). After each session, the floor was cleaned with 97% ethanol to remove odor cues. 
The session duration of 20 minutes was subdivided in 4 equal intervals of 5 minutes for 
later data analyses. The total distance moved (cm) and velocity (cm/s) were measured. 
Home Cage Emergence Test. The home cage emergence test was applied once a week 
throughout the experimental period. In this test, the home cage with the rat was placed 
in the middle of the open field (33). The cage top was left open so that the rat could 
emerge via an easily accessible grid. The latency (in seconds) to emerge from the home 
cage (i.e., the time taken until a rat was on the grid outside its cage with all four legs) 
was scored.  
Biochemical analyses 
Sample collection. One week after cessation of behavioural experiment and drug treat-
ments, the rats were euthanized with thiopentone (150mg/kg i.p). The blood was col-
lected from the aorta in heparinised tubes within 3 to 5 minutes later. The procedure was 
undertaken between 09:00 to 10:00 hours. One ml of whole blood was taken for the 
whole blood stimulation culture, the remainder of the blood was centrifuged, and the 
plasma was collected and stored at -70ºC for subsequent corticosterone analysis. 
 Immediately after blood collection, the rats were decapitated and three brain areas 
(hippocampus, hypothalamus and pre-frontal cortex) were dissected on a frosted glass 
plate and put in sterile chilled PBS (pH7.4—7.6) containing protease inhibitor cocktail 
(Roche) and stored at -70ºC for analysis of cytokines at a later date. 
Plasma corticosterone analysis. Plasma corticosterone was analysed using EIA kit for 
rat and mouse corticosterone from IDS. The detection limit was 18 ng/ml and the intra-
assay coefficient of variation was 3.1%. 
Blood culture and cytokine analysis. The pro-inflammatory IL1β and TNFα, and anti-
inflammatory IL10 cytokines were analysed in both supernatants from stimulated and 
unstimulated cultures. The whole blood was collected at room temperature to prepare 
cultures. Whole blood was cultured in 24-well Costar plate and for each rat, 2 stimu-
lated culture wells and 2 unstimulated culture wells were prepared. In each well 250μl 
of whole blood was incubated at 37°C for 48 hours with 750μl of RPMI 1640 medium 
containing 50μg/ml LPS (Sigma) and 10μg/ml Concanavalin A (Sigma) for the stimu-
lated cultures (34, 35). The RPMI 1640 without mitogens was used for unstimulated 
culture. The supernatants were collected after 48-hour incubation and kept at -70ºC for 
the analysis of cytokines at a later date. The blood cytokines were analysed in duplicate 
using ELISA developed with DuoSet ELISA from R&D System, UK for rat IL1β, 
TNFα and IL10 according to the instructions of the manufacturer. The detection limits 
were 39.06pg/ml for IFNγ and 62.5pg/ml for the other cytokines. The intra-assay 
coefficients of variation were: 3.2% for rat IL1β, 3.5% for rat TNFα and 5.2% for rat 
IL10, respectively. 
Brain cytokine analysis. Brain cytokine analysis was undertaken with the minor modifi-
cation of the previously published methods (36, 37). Brain samples were thawed in an 
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ice bath and sonicated for 20 seconds in cold sterile PBS (pH7.4-7.6) with protease 
inhibitor cocktail (Roche, The Netherlands). The protein concentration was analysed by 
Lowry’s method on sonicated samples (38, 39). The sonicated samples were centrifuged 
and the brain IL1β, TNFα, and IL10 were analysed in duplicate in the supernatant 
diluted with sterile PBS. The brain cytokine levels were were analysed in duplicate 
using ELISA developed with DuoSet ELISA from R&D System, UK for rat IL1β, 
TNFα and IL10 and the concentrations were expressed as pg/mg protein. The detection 
limit for all cytokines was 62.5pg/ml. The intra-assay coefficients of variation were: 
3.2% for rat IL1β, 3.5% for rat TNFα and 5.2% for rat IL10, respectively. 
Data analysis 
 The effect of treatment on behaviour and immune parameters were analysed using 
one-way ANOVA and Bonferroni post-hoc tests were used to perform the pair-wise 
comparison. To determine the significant difference between the 4 groups for the data 
with unequal distribution on K-S D test, non-parametric tests, Mann-Whitney test and 
Kruskal-Wallis test were used. The analysis was carried out using SPSS version 11.5 
and the probability of 0.05 or below was considered to be statistically significant. 
Result 
Behavioural tests 
In open field experiment, there was a significant difference between the groups in both 
distance moved in the first 5 minutes (F=7.66, p=0.001) and the velocity of movement 
in the first 5 minutes (F=7.57, p=0.001). In post hoc Bonferroni test, the OBX group 
showed significantly higher distance moved and velocity moved in the first 5 minutes in 
the open field than the OBX+C group (p=0.008 and 0.008), sham group (p=0.002 and 
0.003) and sham+C group (p=0.004 and 0.002) respectively. 
In home cage emergence test, the Kruskal-Wallis test showed the significant difference 
in latency period between the groups (χ2 = 9.199, p=0.027). The OBX group showed 
significantly shorter latency period compared to sham group (z=-3.192, p=0.001) but 
there is no difference between the other three groups. 
 
Biochemical parameters 
The cytokines concentrations in the supernatant of unstimulated whole blood culture 
and mitogen stimulated whole blood culture of olfactory bulbectomised (BOX) rat 
group, OBX + celecoxib (C) group, sham operated group and sham+C group. No 
statistically significant difference was observed between the groups. 
 Though there was no statistically significant difference in plasma corticosterone 
concentrations between the groups it was slightly higher in OBX group (table 2). 
 No significant difference was found in plasma cytokine concentrations between 
OBX and OBX+C or sham or sham +C groups (table 2). 
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Table-2—Descriptive data on corticosterone concentration in plasma and cytokines concentrations in whole 
blood culture supernatants 
Parameters  OBX 
N=8 
OBX+C 
N=8 
sham 
N=8 
sham+C 
N=8 
Plasma Corticosterone 
(mmol/l) (mean ± S.D) 
280.65 ±180.55 238.79 ±140.35 228.52 ±125.55 240.56 ±130.23 
IL1β (pg/l)  
(mean ± S.D) 
 Unstimulated 
 Stimulated 
 
 
0.00 
89.04 ± 14.18 
 
 
0.00 
71.17 ± 6.07 
 
 
0.00 
86.16 ± 14.82 
 
 
0.00 
94.77 ± 28.55 
TNFα (pgl/l) 
(mean ± S.D) 
 Unstimulated 
 Stimulated 
 
 
20.13 ± 37.97 
411.68±334.29 
 
 
0.00 
359.94±148.84 
 
 
0.00 
436.69±185.88 
 
 
0.00 
504.85±338.80 
IL10 (pg/l) 
(mean ± S.D) 
 Unstimulated 
 Stimulated 
 
 
0.00 
265.28 ± 95.61 
 
 
0.00 
363.82 ±129.82 
 
 
19.99 ± 37.47 
424.04 ±231.25 
 
 
19.57 ± 36.46 
379.99 ±75.12 
  
 
However, in the brain, Kruskal-Wallis test showed significant difference in all three 
cytokines between overall groups in all three brain areas except TNFα in prefrontal 
cortex (table 3). For IL1β, the overall differences between all 4 groups were observed in 
both hypothalamus (p=0.05), hippocampus (p=0.000), and in prefrontal cortex 
(p=0.000) areas. For TNFα, the overall differences between all 4 groups were observed 
in both hypothalamus (p=0.05), hippocampus (p=0.000), but not in prefrontal cortex 
(p=0.067) areas. For IL10, the overall differences between all 4 groups were observed in 
both hypothalamus (p=0.049), hippocampus (p=0.000), and in prefrontal cortex 
(p=0.000) areas. 
 The results from Mann-Whitney test showed (1) in hypothalamus area, OBX group 
showed significantly higher concentration than OBX+C group in IL1β concentrations 
(z=-1.89, p=0.05) and in IL10 (z=-1.995, p=0.046); (2) in hippocampus area, the main 
differences were only between two OBX groups which showed higher concentrations in 
both pro- and anti-inflammatory cytokines and two sham operated groups which 
showed lower cytokines concentrations but no difference between celecoxib treated 
groups and non-treated groups; (3) in prefrontal cortex, OBX group showed signifi-
cantly higher concentrations of TNFα (z=-2.205, p=0.028) and IL1β (z=-3.361, 
p=0.001) than OBX+C group whereas OBX showed significantly lower concentration 
of IL10 (p=-3.361, p=0.001) than OBX+C group.  
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Table-3—Descriptive data on cytokines concentrations in different brain regions 
Parameters  OBX 
N=10 
OBX+C 
N=10 
sham 
N=10 
Sham+C 
N=10 
IL1( (pg/mg) 
(mean ±S.D) 
Hippocampus** 
Hypothalamus* 
Prefrontal cortex** 
 
 
52.42 ± 24.58 
157.65 ± 81.5 
62.51 ± 29.46 
 
 
95.85 ± 51.78 
107.39 ± 46.95 
16.60 ± 5.11 
 
 
15.49 ± 5.7 
108.26 ± 34.67 
29.93 ± 14.27 
 
 
14.49 ± 6.13 
263.09 ±205.99 
18.89 ± 8.39 
TNFα (pg/mg) 
(mean ± S.D) 
Hippocampus** 
Hypothalamus* 
Prefrontal cortex 
 
 
34.28 ± 18.13 
111.37 ± 68.12 
71.32 ± 29.56 
 
 
50.57 ± 28.41 
74.19 ± 31.32 
34.15 ± 16.04 
 
 
7.32 ± 3.3 
66.73 ± 24.38 
39.50 ± 28.49 
 
 
8.29 ± 3.83 
176.38 ± 135.84 
37.12 ± 18.74 
IL10 (pg/mg) 
(mean ± S.D) 
Hippocampus** 
Hypothalamus* 
Prefrontal cortex** 
 
 
129.53 ± 60.14 
337.30 ± 217.71 
36.69 ± 11.26 
 
 
177.49 ± 95.58 
249.53 ±108.24 
113.94 ± 45.09  
 
 
37.28 ± 10.72 
273.92 ± 98.5 
70.26 ± 29.24 
 
 
33.14 ± 10.71 
603.37 ± 446.07 
40.30 ± 16.67 
The cytokines concentrations in the specific brain regions of olfactory bulbectomised (BOX) rat group, OBX 
+ celecoxib (C) group, sham operated group and sham+C group were tested using ELISA. * indicates the 
parameter that showed significant difference at p<0.05 and ** indicates the parameter that showed significant 
difference at p<0.001 between overall groups in Kruskal-Wallis test..  IL = interleukin; TNF = tumour 
necrosis factor 
Discussion 
The behavioural results in this study showed that the hyperactive behaviour of the OBX 
in the first five minutes in the open field was reversed by the chronic celecoxib treat-
ment. In addition, OBX rats also showed similar hyperactive behaviour in home cage 
emergence test compared to sham operated rats and was also reversed by celecoxib 
treatment. The increased exploratory behaviour in the open field apparatus is one of the 
earliest and more robust indices of OBX-related behavioural change (1, 3). However, 
we observed this behaviour only in the first 5 minutes of the 20 minutes in the open 
field and there was no difference in habituation in the later 5-minute sessions. This 
might be due to the less stressful paradigm of our open field arena (40). Nevertheless, 
our data indicated that the increased exploratory behaviour of OBX rats was not ob-
served in those OBX rats treated with celecoxib. 
 Regarding the peripheral cytokine production, both basal and mitogen stimulated 
culture showed no significant difference between the groups. However, in the hypo-
thalamus, both pro-inflammatory IL1β and anti-inflammatory IL10 concentrations were 
increased in the OBX group, but not in OBX+C group. In addition, in prefrontal cortex, 
OBX group showed significantly higher pro-inflammatory cytokines concentrations but 
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lower anti-inflammatory cytokine concentrations compared to OBX+C group. In con-
trast to these areas, in the hippocampus, all three cytokines concentrations were in-
creased in both OBX group and OBX+C group compared to two sham groups. Taken 
together, our results showed that there was an increased inflammatory activity in the 
OBX animals in hypothalamus and prefrontal cortex and that was reversed in the 
OBX+C group in hypothalamus and prefrontal cortex. 
 In macrophage theory of depression (41) it was proposed that the high IL1β pro-
duced by macrophages may stimulate the CRF secretion and induce a hyperactive HPA 
axis. However, in the present study we did not find an increased plasma corticosterone 
secretion in OBX group even though we observed high IL1β concentration in hypo-
thalamus of the OBX rats. The reason might be due to simultaneous increased in IL1β 
and IL10 concentrations in the hypothalamus that produced a balance between pro- and 
anti-inflammatory cytokines which in turn prevented the significant increase in HPA 
axis activity. It is also possible that, as we collected the blood samples for biochemical 
analyses during the day time under euthanasia, and that might mask the difference in 
plasma corticosterone concentrations. A hypersecretion of corticosterone in OBX rats 
during the dark phase of the light-dark cycle, but not during the light phase, has also 
been reported previously (11). 
 The high pro-inflammatory cytokines concentrations and low anti-inflammatory 
cytokine IL10 concentration in prefrontal cortex might be the reason for the behavioural 
changes in OBX rats in our study. In patients with major depression, neuroimaging and 
post-mortem studies have identified neurobiological and neurophysiological abnormali-
ties in multiple areas of the prefrontal cortex and its linked brain regions (42-46). The 
COX-2 inhibitor celecoxib was also proven to improve the depressive symptoms in 
patients with major depression (32). Those findings supported our findings that the 
chronic celecoxib treatment reversed both the behavioural and prefrontal cortex cyto-
kine changes in OBX+C group. 
 It may be concluded that the COX-2 inhibitor celecoxib reverses these changes 
induced by the lesions of the olfactory bulb by blocking the pro-inflammatory cytokines 
in prefrontal cortex that might result in the reduction in PGE2. In addition, the synergis-
tic effect of reduction in both IL1 and TNF may also impact on the release of PGE2 (47). 
The possible link between the change in PGE2 following COX-2 inhibitor and the 
synthesis of serotonin in the cortex of the rat brain has been reported (48). It therefore 
seems possible in the rat that the normalisation of the behaviour of the OBX rats in the 
present study could be associated with the increase in the brain serotonin since low 
brain serotonergic activity OBX rat model has been reported (49). 
 Nevertheless, the results of our study supported the clinical observation that the 
COX-2 inhibitor celecoxib may exhibit antidepressant properties by reducing the 
inflammatory changes in the brain. 
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Abstract 
Background: The neurodegeneration hypothesis proposed major depression as a 
consequence of imbalance between neuroprotective and neurodegenerative metabolites 
in kynurenine pathway.  
Method: To test the hypothesis, the plasma tryptophan and kynurenine pathway me-
tabolites were studied in 58 patients with major depression and 189 normal controls. 
Result: The mean tryptophan breakdown index was higher (p=0.036), and mean 
kynurenic acid concentration and mean neuroprotective ratios were lower, in depressed 
patients (p=0.003 and 0.003, respectively). In receiver-operating characteristic analysis, 
the kynurenic acid concentrations and the neuroprotective ratio showed clear discrimi-
nation between depressed patients and control with area under the curve 79% and 76.3% 
respectively. The neuroprotective ratio did not change after treatment in those with 
repeated episodes of depression but it increased significantly (p=0.044) in those with 
first episodes.  
Conclusion: The results suggested that the reduction in neuroprotective markers, which 
indicated an impaired neuroprotection, may play an important role in pathophysiology 
of major depression. 
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Introduction 
It has been documented that pro-inflammatory cytokines such as interferon-α could 
induce depression (1-3) and there is a body of evidence that pro-inflammatory cytokines 
are higher in depressed patients compared to their controls (4, 5).The high tryptophan 
breakdown, and a low kynurenic acid concentration, in the blood of the patients with 
hepatitis C who had been treated with the pro-inflammatory cytokine interferon-α and 
suffered from depressive like symptoms, was recently reported (6, 7). 
 Tryptophan depletion is the result of enhanced tryptophan catabolism by the trypto-
phan 2,3-dioxygenase (TDO) in the liver (8) and the indoleamine 2,3-dioxygenase 
(IDO) in the lungs, placenta, blood and the brain (9, 10). The TDO specifically metabo-
lises tryptophan only (8) whereas IDO also metabolises serotonin and melatonin (11). 
Recently, TDO2 immunoreactivity was demonstrated in frontal cortex of the schizo-
phrenic brain (12) though its exact role in the brain is still controversial. The activity of 
TDO is enhanced by the tryptophan concentration (13-15) and by high cortisol (16) 
whereas IDO activity is enhanced by the pro-inflammatory cytokines such as interferon-
γ (17-21) and inhibited by anti-inflammatory cytokine, IL4 (22). Both persistent hyper-
cortisolaemia (23-26) and the increased pro-inflammatory cytokines (4, 5, 27-32) have 
been reported in patients with major depression. 
 After tryptophan is first catabolised into kynurenine, there is further catabolic 
pathway, the kynurenine pathway, in which the metabolites contribute to the neuropro-
tective-neurodegenerative changes in the brain. Kynurenine is further catabolised into 3-
hydroxy kynurenine (3OHK) and the NMDA receptor agonist quinolinic acid (33, 34) 
(figure 1). The 3OHK causes neuronal apoptosis (35) while quinolinic acid causes 
excitotoxic neurodegenerative changes (36). However, kynurenine can also be catabo-
lised into kynurenic acid (figure 1) which is NMDA receptor antagonist (37) and is 
protective against excitotoxic action of quinolinic acid (38, 39). 
 In the brain, tryptophan catabolism occurs in the astrocytes and microglia (40-42) 
though 60% of brain kynurenine was contributed from the periphery (43). The astro-
cytes were shown to produce mainly kynurenic acid whereas microglia and macro-
phages produced mainly quinolinic acid (44-46). The astrocytes were also demonstrated 
to metabolise the quinolinic acid produced by the neighbouring microglia (45). The 
protective effect of kynurenic acid against excitotoxic effect of quinolinic acid has also 
been detected in neuronal cell cultures (38). 
A study of quinolinic acid concentration in the blood of patients with different major 
psychiatric disorders and neurodegenerative disorders failed to show high quinolinic 
acid concentration in depressed patients (47). However, the importance of the distur-
bance in the balance between the kynurenic acid and quinolinic acid, the neuroprotec-
tive-neurodegenerative balance in the brain of the patients chronic depression, has been 
proposed in the neurodegeneration hypothesis of depression (48). 
 Though the cytokine changes in depression have been well documented, the role of 
tryptophan metabolism in terms of the balance between neuroprotection and neurode-
generation in major depression has never been explored. To test whether the enhanced 
tryptophan breakdown, and the imbalance in neurodegenerative and neuroprotective 
metabolites in kynurenine pathway, are involved in the pathophysiology major depres-
sion, the changes in tryptophan and kynurenine pathway metabolites were therefore 
explored in the plasma of depressed patients and healthy controls.   
 87 
CHAPTER 6 
 
 
Figure 1. Kynurenine pathway 
 
Above figure explains briefly on tryptophan catabolic pathway. It demonstrates that after tryptophan is 
catabolised into kynurenine, it is further catabolised into quinolinic acid and kynurenic acid. 
5-HT = 5-hydroxy tryptamine (serotonin); IDO = indoleamine 2,3-dioxygenase; NAD = nicotinamide adenine 
dinucleotide 
Materials and Methods 
Subjects 
Among psychiatric patients admitted to the Psychiatry Department, Korea University 
Medical Centre, during the period from 2002 to 2004, 58 patients with major depression, 
who met the Diagnostic and Statistical Manual (DSM-IV) criteria based on clinical 
interviews using a Structured Clinical Interview for DSM-IV (49), were recruited. 
Among them, 52% were drug naïve, 10% were drug free for at least 4 months and 38% 
were on antidepressant treatment. This study was approved by the institutional ethical 
committee of Korea University and informed consent was taken from each subject and 
patient. 
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 The psychopathological status of the patients was assessed by a trained physician 
using the Brief Psychiatric Rating Scale (BPRS) (50) and the Hamilton Depression 
Rating Scale (HDRS) (51) on admission and at the end of 6 weeks anti-depressant trial.  
 Out of the 58 patients, 40 patients (male:female, 1.2:1; age, 44.62 ± 14.67 years) 
who agreed to be hospitalised during the 6-week study were included in the second part 
of the study to compare the change in the tryptophan metabolism after antidepressant 
treatment. Among these, 60% were treated with selective serotonin reuptake inhibitors 
(SSRI), 21.3% with tricyclic antidepressants, 8.4% with Serotonin Noradrenalin Reup-
take Inhibitor (SNRI), 6.4% with SSRIs and mood stabilizer and 4.3% with SSRIs and 
antipsychotics (risperidone or olanzapine). 
 The patients who had history of any concomitant psychiatric illness, such as sub-
stance or alcohol abuse, or history of infection or known autoimmune disease were 
excluded. The patients found to have any abnormality in blood (blood glucose, choles-
terol, renal, thyroid and liver function, Venereal Disease Research Laboratory tests) and 
urine tests or in electrocardiogram (ECG) and electroencephalogram (EEG), were also 
excluded. The laboratory tests were rechecked after 6 weeks. 
 A total of 189 healthy controls (male:female, 1:1.2; age, 32.49 ± 10.69 years) were 
recruited among apparently healthy individuals who visited the hospital for regular 
health screening during the same period. Those with any history of past psychiatric 
illness, diagnosed autoimmune disease, or substance or alcohol abuse were excluded. 
All subjects were free from any physical illness for at least 2 weeks before the study. 
They showed normal laboratory findings in blood chemistry (blood glucose, cholesterol, 
renal, thyroid and liver function), Venereal Disease Research Laboratory tests, chest X-
ray, and ECG. 
Biochemical analysis 
Fasting venous blood (10 ml) was withdrawn with a lithium heparin vacuum tube 
between 8:00-9:00 A.M. Plasma was separated immediately and stored at –70ºC. For 
the depressed patients, blood was sampled again at 6 weeks later. The high performance 
liquid chromatography was used to measure plasma tryptophan, competing aminoacids 
(tyrosine, valine, phenylalanine, leucine, isoleucine) according to the method of Cooper 
et al (52), to measure plasma kynurenine, kynurenic acid and 3-hydroxyanthranilic acid 
(3HAA) (the metabolite from degenerative pathway, one step before quinolinic acid) 
according to the method of Hervé et al (53). 
 The tryptophan and competing aminoacids were analysed in the plasma samples 
using reversed phase high performance liquid chromatography (HPLC) with Chromolith 
Performance PR-18e, 4.7x100mm column (Merck, Darmstadt, Germany). Amino acids 
were detected fluorimetrically at an excitation wavelength of 340 nm and an emission 
wavelength of 440 nm after derivatisation with o-phtalicdialdehyde and on-line mi-
crodialysis by an ASTED autosampler (Gilson, Viliers le Bel, France). The mobile 
phase was set in gradient by mixing Solvent A (57.2 g Na2HPO4.12H20 and 160 ml of 
Acetonitrile in Milli Q water which is made to total 2 litres, pH 6.5) and Solvent B (420 
water/280 ACN/320 MeOH). The different aminoacid standards (tyrosine, valine, 
tryptophan, phenylalanine, isoleusine and leusine) are prepared as stock by weighing off 
100 mg of each compound and dissolving in Milli Q water in a 100ml measuring flasks. 
For Working Standard solution, 5 ml of those aminoacid stock standards are diluted 
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with Milli Q water. Norvaline 0.5mg/ml was used as internal standard. Borate buffer 
(pH 9.5) was used for dialysis of the sample. 
 The kynurenine, kynurenic acid and 3HAA were analysed in the deproteinised 
plasma samples using reversed phase high performance liquid chromatography (HPLC) 
with Chromolith performance PR-18e, 4.7x100mm column (Merck, Darmstadt, Ger-
many). Kynurenine was detected spectrophotometrically at 365 nm, kynurenic acid was 
detected fluorimetrically at an excitation wavelength of 334 nm and an emission wave-
length of 388 nm and 3HAA was detected fluorimetrically at an excitation wavelength 
of 316 nm and an emission wavelength of 420 nm. The mobile phase was prepared with 
250 mM Zinc-acetate in distilled water (27.4 g in 500 ml) and pH was brought to 5.8 
with acetic acid and made up to a volume of 455 ml with water. A total of 45ml acetoni-
trile was added into this mixture. The kynurenine standards were prepared by dissolving 
kynurenine in water and kynurenic acid standards were prepared by dissolving 
kynurenic acid ethanol and hydrochloric acid. For working standards, the stock stan-
dards of 5µM for kynurenine (500 µl) and 100 nM for kynurenic acid (10.0 µl) were 
diluted in distilled water. Perchloric acid was used for deproteinization. 
 The intra- and inter-assay coefficient of variations ranged from 5% to 7% for all the 
metabolites. To avoid the effect of inter-assay variation, the samples from both de-
pressed patients and normal controls were mixed alternately in each set of analyses. To 
avoid the operator bias the samples’ order was arranged by the investigator and the 
laboratory technician was blind to the information of the sample whether depressed or 
normal. For each 20 samples 3 standards and one quality control sample (pooled drug 
free EDTA plasma) were used as quality control. 
Calculations 
The tryptophan index that indicated the tryptophan availability in the brain was taken as 
the ratio between plasma tryptophan and the competing amino acids. 
 Tryptophan index = 100 x plasma tryptophan (μmol/l) 
    Sum of plasma CAA (μmol/l) 
 
The plasma CAA value was the sum of plasma tyrosine, valine, phenylalanine, leucine, 
isoleucine values. 
The tryptophan breakdown index, that indirectly indicated the sum of the activities of 
TDO and IDO, was calculated as shown; 
 Tryptophan breakdown index = plasma kynurenine (μmol/l) 
       plasma tryptophan (μmol/l) 
 
The ratio between plasma kynurenic acid and plasma kynurenine, from which kynurenic 
acid and quinolinic acid are formed, enabled the neuroprotective ratio to be determined; 
 Neuroprotective ratio = 1000 x plasma kynurenic acid (nmol/l) 
       plasma kynurenine (nmol/l)  
Data analysis 
 Since the means of the age of controls and depressed were significantly different, 
the data was analysed in whole group by controlling age and gender in multivariate and 
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univariate analyses and also by dividing the 2 different age groups (younger than 40 
year age group and between 40 to 50 year age group). The comparison of the mean 
values of the parameters, that showed normal distributions between depressed patients 
and controls, were analysed using Students ‘t’ test. The comparison of the parameters 
with normal distribution in the patients on admission and at the time of discharge, were 
analysed using paired ‘t’ test. For the parameters which are not normally distributed in 
K-S D test, the comparison within group was analysed using Wilcoxon signed rank test 
and the comparison between groups was analysed using Mann-Whitney test. Multivari-
ate analysis was used to determine the differences in kynurenic acid and neuroprotective 
ratio between depressed patients and controls when age and gender were controlled. 
Univariate analysis was applied to determine the effect of body mass index, subtype of 
depression, number of previous episodes of depression, medication before admission 
and suicidal attempts on the plasma tryptophan, kynurenine, 3HAA, kynurenic acid and 
the neuroprotective ratio on admission when age and gender were controlled. This 
analysis was also applied to the effect of the type of antidepressant administered on the 
plasma tryptophan, kynurenine, 3HAA, kynurenic acid and the neuroprotective ratio at 
the time of discharge. The Receiver Operating Characteristic (ROC) Curve analysis was 
used to find the cut-off point and to determine the discrimination between depressed 
patients and controls using kynurenic acid and the neuroprotective ratio. The SPSS 
11.05 version was used for the statistical analyses and the ‘p’ value of 0.05 and below 
was considered significant. 
Results 
General characteristics 
Table 1. General characteristics of the depressed patients 
Parameters Depressed 
n=58 
Controls 
N=189 
Gender (Male:Female) 1.2:1 1:1.2 
Age (years) (mean±SD) 44.62 ± 14.67 32.49 ± 10.69 
BMI (mean±SD) 21.44 ± 3.03 22.11 ± 2.99 
Subtypes of depression (%) 
 Melancholic 
 Atypical 
 Psychotic 
 Disthymic 
 
60.3 
15.5 
22.4 
1.7 
 
HDRS (mean±SD) 27.21 ± 7.26  
Previous history of depression (%) 48  
Onset of major depression (months) (range) 10 - 62  
Suicidal attempt (%) 17.2  
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Table 1 shows the general characteristics of the patients and the control subjects. There 
was no significant difference between body mass index (t=-1.36, p=0.175) and gender 
ratio (male:female, 1.2:1 vs 1:1.2) between the depressed patients and the controls. 
However, the mean age was higher in depressed patients than the controls (t=5.840, 
p=0.000). 
Depressed patients versus normal controls 
Though the mean plasma CAA and mean plasma tryptophan concentrations showed no 
difference between the patients and controls, the mean tryptophan index in the de-
pressed patients was significantly lower than that of the controls (p=0.045). The mean 
tryptophan breakdown index of the depressed patients was significantly higher than in 
the controls (p=0.036). The mean plasma kynurenine values showed no difference 
between the groups. The mean plasma kynurenic acid values and the mean neuroprotec-
tive ratios, showed highly significant differences between the depressed patients and the 
controls (p=0.003 and p=0.003, respectively) when age and gender were controlled. A 
comparison of the biochemical parameters between the depressed patients and the 
controls were shown in the table 2. 
 The univariate analyses showed that there were no effects of body mass index, 
subtype of depression, number of previous episodes of depression, duration of illness, 
medication before admission and suicidal attempts on plasma kynurenic acid values and 
neuroprotective ratios when age and gender were controlled. The HDRS score showed 
no significant correlation with the plasma kynurenic acid values or the neuroprotective 
ratios. 
Table 2. Biochemical parameters of depressed patients on admission vs normal controls 
Parameters Depression 
N=58 
Normal control 
N=189 
‘p’ value 
 
Plasma CAA 
(μmol/l)  
664.91 ± 123.25 650.73 ± 132.21 0.453 
Plasma Tryptophan (μmol/l)  65.80 ± 15.57 69.71 ± 13.65 0.066 
Tryptophan index 
 
9.99 ± 1.88 10.87 ± 1.67 0.045 
Tryptophan breakdown† 
 
0.025 ± 0.012 0.017 ±0.014 0.036 
Plasma Kynurenine 
(μmol/l)  
1.81 ± 0.56 1.87 ± 0.43 0.475 
Plasma hydroxyanthranilic acid 
(μmol/l) 
24.53 ± 11.91 24.12 ± 7.3 0.851 
Plasma Kynurenic acid ‡ (nmol/l)  24.29 ± 8.09 35.95 ±13.4 0.003 
Neuroprotective ratio ‡ 
 
14.08 ± 4.37 19.36 ± 5.89 0.003 
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Note: All the parameters were expressed in mean±SD and were compared using ‘t’ test except those indicated 
with † for which Mann-Whitney test was used and ‡ for which multivariate analysis was used. 
 The ROC curve analysis for the plasma kynurenic acid showed that the area under 
the curve was 79%. With the cut-off point of 27.625 nmol/l of plasma kynurenic acid, 
the depressed patients and normal controls could be differentiated with the sensitivity of 
74.5% and the specificity of 70.5%. The ROC curve analysis for the neuroprotective 
ratio showed that the area under the curve was 76.3%. With the cut-off point of 16.05 of 
plasma kynurenic acid, the depressed patients and normal controls could be differenti-
ated with the sensitivity of 70.5% and the specificity of 68.1%. 
 Even though patients and controls were subdivided into two age groups, the signifi-
cance of the parameters did not change (table 3). 
 
Table 3. Biochemical parameters of depressed patients on admission vs normal controls in two different age 
matched groups. 
Parameters Age below 40 Age 40 to 50 
 Depression 
N=25 
Normal control 
N=145 
Depression 
N=30 
Normal control 
N=44 
Age (years) 
 
30.39 ± 7.02 27.84 ± 6.40 44.28 ± 3.29 44.00 ± 2.95 
Plasma Tryptophan 
(μmol/l) 
66.46 ± 13.46 68.36 ± 15.06 66.51 ± 15.88 67.49 ± 13.05 
Tryptophan index 
 
10.01 ± 1.61* 10.81 ± 1.80 10.72 ± 2.13* 11.05 ± 1.87 
Tryptophan breakdown† 
 
0.026 ± 0.005* 0.017 ±0.013 0.025 ± 0.011* 0.017 ±0.016 
Plasma Kynurenine 
(μmol/l) 
1.80 ± 0.67 1.83 ± 0.38 1.65 ± 0.42* 2.05 ± 0.61 
Plasma hydroxyanthranilic 
acid (μmol/l) † 
29.16 ± 13.74 24.68 ± 7.64 22.51 ± 13.67 25.20 ± 6.08 
Plasma Kynurenic acid 
(nmol/l)  
24.22 ± 9.92** 35.47 ±12.93 24.43 ± 5.27** 41.24 ±14.76 
Neuroprotective ratio 
 
14.12 ± 4.32** 19.34 ± 5.97 15.69 ± 4.89** 20.88 ± 5.38 
Note: All the parameters were expressed in mean±SD and were compared using ‘t’ test except those indicated 
with ‘†’ which were analysed using Mann-Whitney test. (*) indicated the difference from age matched normal 
control at ‘p’ value <0.05 and (**) indicated the difference from age matched normal control at ‘p’ value of 
0.001. 
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Depressed on admission versus depressed at discharge 
There were no significant differences in mean tryptophan index, mean plasma 
kynurenine and mean plasma kynurenic acid though there was an increase in tryptophan 
breakdown index. In general, the mean neuroprotective ratio in all the depressed pa-
tients between admission and discharge showed no significant difference (table 4). 
However, the neuroprotective ratio of those patients with first episode of depression 
increased significantly after treatment (12.43±3.01 before vs 15.24±4.98 after, t=2.234, 
p=0.044) whereas in those with repeated episodes, there was no change. 
 The change of neuroprotective ratio showed no correlation with change of HDRS 
after treatment (r = -0.088, p= 0.552). The HDRS after treatment was 7.56±6.67. 
The univariate analysis showed no effect of type of antidepressant given on the plasma 
kynurenic acid values and neuroprotective ratios when age and gender were controlled. 
 
Table 4. Biochemical parameters of depressed patients on admission vs discharge 
Parameters Depressed patients 
(admission) 
N=40 
Depressed patients 
(discharge) 
N=40 
‘p’ value 
(Paired‘t’ test) 
Plasma CAA 
(μmol/l)  
657.88 ± 134.95 691.73 ± 147.16 0.290 
Plasma Tryptophan (μmol/l)  67.0 ± 16.29 67.48 ± 17.87 0.846 
Tryptophan index 
 
10.27 ± 1.78 9.84 ± 2.05 0.937 
Tryptophan breakdown index ††  0.028 ± 0.11 0.035 ± 0.19 0.033 
Plasma Kynurenine 
(μmol/l)  
1.90 ± 0.61 2.04 ± 0.58 0.220 
Plasma Kynurenic acid (nmol/l)  24.02 ± 9.08 27.80 ± 9.98 0.122 
Neuroprotective ratio 
 
13.12 ± 4.06 14.01 ± 4.45 0.356 
Note: All the parameters were expressed in mean±SD and were compared using paired ‘t’ test except Trypto-
phan breakdown index indicated with †† for which Wilcoxon signed rank test was used. 
Discussion 
The results of this study showed that there was a lower tryptophan availability and 
higher tryptophan breakdown in the depressed patients even though there was no sig-
nificant difference in plasma tryptophan concentration. However, while there was no 
significant difference in plasma kynurenine concentrations between the patients and the 
controls, there was a significantly lower mean plasma kynurenic acid concentration in 
the depressed patients. Moreover, there was no difference in plasma 3-hydroxy-
anthranilic acid concentration. 
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 Since there is no difference in BMI, plasma tryptophan and plasma CAA concentra-
tions between depressed and their controls, the low tryptophan index is unlikely to be 
due to the poorer nutritional status of the depressed patients. Furthermore, while there 
was no significant difference in plasma kynurenine concentrations, there was a higher 
tryptophan breakdown index in the depressed patients. This suggests that the kynurenine 
formed by tryptophan breakdown was further metabolised at a faster rate in the de-
pressed patients. Kynurenine is again metabolised either into the toxic quinolinic path-
way, in which 3OHK, 3HAA and finally quinolinic acid were produced, or into 
kynurenic pathway, in which neuroprotective kynurenic acid is the final metabolite (33, 
34, 36-38). However, as the plasma kynurenic acid concentration in the depressed 
patients was significantly lower than the control subjects, it is suggested that the me-
tabolism of kynurenine is preferentially directed into quinolinic pathway. The reduced 
formation of the neuroprotective metabolite, kynurenic acid, thereby may contribute to 
an imbalance in the neuroprotection and neurodegeneration pathways. As it was not 
possible to determine the plasma 3-hydroxykynurenine and quinolinic acid concentra-
tion in this study, only 3HAA was measured. The plasma 3HAA acid concentrations in 
patients and controls were not different. However, the conclusion could not be drawn as 
there was no increase in degenerative metabolites. That may also indicate the faster 
formation of neurotoxic quinolinic acid from 3HAA or slower degradation of neuro-
toxic 3OHK. Moreover, the kynurenic acid/kynurenine ratio was taken as the index of 
neuroprotection and this ratio was found to be significantly lower in depressed patients. 
 The above finding is in agreement with that of Wichers et al (6), in which the 
neurotoxic challenge was higher in those hepatitis C patients treated with interferon-α 
and developed symptoms of depression. 
 In ROC curve analyses, both the plasma kynurenic acid concentration and the 
neuroprotective ratio showed high discrimination between depressed patients and their 
controls with high sensitivities and specificities. Moreover, there was no relationship 
between the subtypes of depression, previous medication and episodes and duration of 
onset of depression, on the plasma kynurenic acid concentration and neuroprotective 
ratio. In addition, it was well documented that 60% of the kynurenine in the brain was 
contributed from the periphery (43). Therefore, based on the findings in this study, the 
impaired neuroprotection in depression could clearly be considered. 
 In addition, overall these markers did not show significant change after the 6-weeks 
of antidepressant treatment regardless of the HDRS score in depressed patients. 
Whereas the tryptophan breakdown was increased after treatment, which explained the 
slight increase in plasma kynurenine and kynurenic acid concentrations, the mean 
neuroprotective ratio did not change. When analyses were performed on the subgroups 
in terms whether they had the first episode or repeated episodes of depression, the mean 
neuroprotective ratio significantly increased in those patients with first episode though it 
was still below the values of controls, whereas there was no change in those with 
repeated episodes. This indicates that though the antidepressants corrected the depressed 
symptoms they did not correct the impaired neuroprotection in patients who had suf-
fered repeated episodes of depression. This suggests that the chance of the reversibility 
of impaired neuroprotection become less with recurrence and chronicity. 
 It was reported that quinolinic acid selectively induces apoptosis of human astro-
cytes (54). In major depression, shrinkage of hippocampus (55, 56), astrocytes and 
neuronal loss in prefrontal cortex (57-59) and in striatum (60, 61) have been reported. 
These observations supported the present findings since astrocytes are the important 
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source of kynurenic acid in the brain (44-46) and apoptosis of astrocytes could result in 
lower neuroprotective action against neurodegenerative quinolinic acid and thus con-
tributes to loss of neurones and to the likelihood of treatment resistance. This might lead 
to further apoptosis of astrocytes, further decrease in kynurenic acid and further loss in 
neuroprotective activity as depression enters a chronic phase. The elevated astrocyte 
marker protein S100B in plasma (62-66) and cerebrospinal fluid (67) of depressed 
patients was also observed and those findings further supported the possibility of the 
involvement of astrocytes in pathophysiology of depression. Moreover, the effect of 
chronic stress on astroglial plasticity in hippocampus was observed and inability of 
fluoxetine to normalise this defect was documented in an animal experimental study 
(68). 
 The limitation in this study was that the strong neurotoxic metabolites, plasma 
quinolinic acid and 3OHK could not be measured. A future study has been planned to 
measure plasma 3OHK together with the enzymes responsible for the synthesis and 
metabolism of the components of the kynurenine pathway. 
 In conclusion, the findings of this study support the neurodegeneration hypothesis 
(48) in which an impairment in neuroprotective components of the kynurenine meta-
bolic pathway contributes to chronic depression. 
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Summary 
Epidemiological studies show that there is a correlation between chronic depression and 
the likelihood of dementia in later life. There is evidence that inflammatory changes in 
the brain are pathological features of both depression and dementia. This suggests that 
an increase in inflammation induced apoptosis, together with a reduction in the synthe-
sis of neurotrophic factors caused by a rise in brain glucocorticoids, may play a role in 
the pathology of these disorders. A reduction in the neuroprotective components of the 
kynurenine pathway, such as kynurenic acid, and an increase in the neurodegenerative 
components, 3- hydroxykynurenine and quinolinic acid, contribute to the pathological 
changes. Such changes are postulated to cause neuronal damage and thereby predispose 
chronically depressed patients to dementia. 
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Introduction 
Epidemiological studies have implicated chronic depression as an important predispos-
ing factor for dementia in later life. Depression has been shown to be a common antece-
dent of Alzheimer’s disease, and may be an early manifestation of dementia before the 
cognitive symptoms become apparent (1, 2). In particular, patients with depression who 
later develop dementia, usually have a poorer base-line performance in cognitive tasks 
(3). 
 Several studies have shown that depression is a risk factor for dementia, particularly 
Alzheimer’s disease, and this may be particularly important if the depressive episode 
occurs within 2 years of the diagnosis of dementia (3). Indeed, it has been estimated that 
patients with mild cognitive impairment and depression have more than twice the risk of 
developing dementia than those of the same age but who do not have depression. This 
suggests that depression may be a prodrome of dementia (4). 
 Both depression and dementia are associated with inflammatory changes in the 
brain. The chronic inflammatory diseases such as rheumatoid arthritis are frequently 
associated with depression (5), while pro-inflammatory cytokines such as interferon α 
(IFNα), used therapeutically in the treatment of hepatitis for example, are known to 
precipitate depressive episodes in psychiatrically non-depressed patients (6). An ex-
perimental study have also been reported in rats treated with IFNα showed anxiety 
behaviour in open field and changes in cytokines in both periphery blood and in certain 
brain regions (7). Numerous clinical studies, supported by clinical evidence, have 
shown that pro-inflammatory cytokines are raised in the blood of depressed patients (8). 
Such observations supported the macrophage theory of depression (9). 
 The possible link between depression, dementia and inflammatory changes in the 
brain is also supported by clinical and experimental studies of acquired immune defi-
ciency syndrome (AIDS). It is well established that when human immunodeficiency 
virus (HIV)-infected patients develop AIDS, a substantial proportion of the patients also 
develop depression (10). Depression is one of the early manifestations of HIV dementia 
(11). Antiretroviral therapy was also one of those early manifestations (11). The ex-
perimental study in rodent showed that Efavirenz, the antiretroviral drug used in treat-
ment of HIV infection induced increased proinflammatory cytokines in the peripheral 
blood and was associated with anxiety behaviour and impaired spacial memory (7). 
Thus both depression and dementia are associated with inflammatory changes. 
 As there is pathological evidence that increased apoptosis occurs in both chronic 
depression and dementia resulting in atrophic changes in the hippocampus, frontal 
cortex and other brain regions (12-14), it has been speculated that the increase in in-
flammatory mediators, such as interleukin (IL)1, TNFα and prostaglandin E2 (PGE2), 
play a central role in the pathology of these conditions. The results of clinical and 
experimental research therefore lead to the conclusion that an increase in apoptosis 
caused by inflammation, together with a reduction in the synthesis of neurotrophic 
factors such as brain derived neurotrophic factor (BDNF) that assists in the repair of 
damaged neuronal networks, provide a basis for the pathological changes that are 
common to depression and dementia . The following reviews the evidence in favour of 
this hypothesis. 
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Changes in the hypothalamic-pituitary-adrenal axis in depression 
and dementia 
Stressful life events trigger neurotransmitter changes in the brain via an activation of the 
corticotrophin releasing factor (CRF) pathway that terminates not only within the 
hypothalamus and other parts of the central endocrine system but also on the locus 
coeruleus and raphe nuclei (15). This provides a biological link between stressful 
stimuli and the changes in the endocrine, immune and neurotransmitter systems that are 
involved in the psychopathology of depression (figure 1). 
 Investigations of the role of the hypothalamo-pituitary-adrenal (HPA) axis in the 
psychopathology of depression commenced over 40 years ago when it was reported that 
depressed patients have a higher circulating plasma cortisol concentration than those 
that are not depressed (16, 17). At this time, the dexamethasone suppression test (DST) 
was developed to provide a functional assessment of HPA axis activity. It was discov-
ered that this synthetic glucocorticoid would normally suppress the secretion of cortisol  
 
Figure 1—Relationship between stress, activation of limbic regions of the brain by CRF, and the consequent 
changes in the adrenal cortex and the sympathetic system. (+), activation, (-), inhibition. In chronic stress or 
depression, the feedback inhibitory loop malfunctions following the desensitization of the central glucocorti-
coid receptors in the brain and immune cells. This results in hypercortisolaemia, a common feature of both 
major depression and Alzheimer’s disease. Anxiety, a common comorbidity symptom with major depression, 
is associated with the increased activity of the central and peripheral sympathetic systems. CRF, corticotro-
phin releasing factor; NA, noradrenaline; AVP, arginine vasopressin; Ach, acetylcholine; ACTH, adrenocor-
tico-trophic hormone; PVN, paraventricular nucleus. 
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by activating hypothalamic and pituitary glucocorticoid receptors thereby suppressing 
the secretion of CRF and adrenocorticotrophic hormone (ACTH) which, in turn, re-
duced the activation of the adrenal cortex and the release of cortisol. The mechanism 
whereby these changes occurred was explained in terms of a negative feed-back loop 
whereby the raised plasma glucocorticoid concentration controls the further release of 
the steroid. However, it soon became apparent that in patients with major depression, 
the negative feed-back loop ceased to function due to the desensitisation of the central 
glucocorticoid receptors. The negative DST thereby became a diagnostic marker of 
melancholic depression (18). 
 Nevertheless, it is now apparent that the DST lacks both specificity and sensitivity 
for depression (19) even though it may still offer ‘reliability in the assessment of the 
severity of depression (20). Hypercortisolism and a negative DST are now known to 
occur in patients with Alzheimer’s disease and alcoholism for example (21). Further-
more, it has been estimated that only 60% of patients with major depression show a 
negative DST. Nevertheless, these findings do serve to emphasise the importance of the 
HPA axis in psychiatric disorders. 
 It is frequently assumed that the synthetic glucocorticoids such as dexamethasone, 
act on glucocorticoid receptors in an identical manner to the natural glucocorticoids 
such as cortisol. However, this may not be the case. Dexamethasone acts primarily on 
the glucocorticoid receptors in the anterior pituitary, does not readily enter the brain and 
therefore differs substantially from natural glucocorticoids that activate both mineralo-
corticoid and glucocorticoid receptors (22). There is also evidence that while dexa-
methasone may reduce the release of CRF, it does not suppress the release of arginine 
vasopressin (AVP). There is evidence that AVP, not CRF, is the main activator of the 
HPA axis due to chronic stress and major depression (23, 24). The increased action of 
AVP is further exacerbated by the action of IL1β; chronically administered IL1β has 
been shown to cause a shift in the role of CRF to AVP in the activation of the anterior 
pituitary (25). In addition, it has been shown that there is an age-related increase in the 
co-localisation of AVP in CRF neurons in patients with major depression and dementia 
(26). Thus it seems reasonable to conclude that the hypersecretion of cortisol in patients 
with depression or dementia may at least be partly a consequence of an increased 
activation of the HPA axis by AVP. 
 Additional evidence for the change in the functional activity of the pituitary gland is 
provided by the finding that the adrenals and the pituitary are enlarged in those with 
depression (27, 28), these changes being associated with a hypersecretion of CRF (29). 
Furthermore, the density of the CRF receptors in the frontal cortex is reduced, presuma-
bly as a consequence of the hypersecretion of CRF (30, 31). The hypersecretion of CRF 
would appear to be a state, rather than a trait, marker of depression (32). 
 If hypercortisolaemia is a common feature of major depression and some types of 
dementia, it would be anticipated that immunosuppression would be a common feature 
of these conditions. However, it is apparent that both immunosuppression (for example, 
of natural killer cell [NKC] activity) and immune activation (for example, macrophage 
activation) are common features of depression. One possible explanation is that an 
increased vulnerability to environmental stress, which is a common feature of both 
depression and dementia (33), elicits a bi-directional, homeostatic interaction between 
the endocrine and immune system. Thus CRF has been associated with humoral activa-
tion that results in an increased release of pro-inflammatory cytokines. By activating the 
HPA axis, pro-inflammatory cytokines not only further release of CRF but also lead to 
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glucocorticoid resistance thereby impairing the regulatory feedback mechanism . Con-
versely, the increase in the concentration of plasma cortisol , together with the increased 
sympathetic activity that is a normal feature of the stress response, suppresses NKC and 
T-cell replication. There is evidence that activation of the β-adrenoceptors on the NKC 
membrane, and that results in the decrease in activity of the NKCs, occurs independ-
ently of the activation of the HPA axis (33). Clearly the interaction between the immune 
system and the HPA axis is both complex and interdependent.  
 In the past 20 years, attention has focussed on changes in the hypothalamic-
pituitary-adrenal axis, together with the biogenic amine neurotransmitters noradrenaline, 
serotonin and, to a lesser extent dopamine (34, 35). More recently however it has 
become apparent that both major depression and chronic stress result in more persistent 
structural changes in the brain as a consequence of the decrease in the synthesis of 
neurotrophic factors, such as brain derived neurotrophic factor (BDNF) and the anti-
apoptotic factor bcl-2 (36). These changes are attributed to the chronic increase in brain 
glucocorticoids that arise due to the desensitisation of central glucocorticoid Type 2 
receptors that occur as a consequence of the reduction in the inhibitory feedback 
mechanism (37). Such effects contribute to the failure in brain repair mechanisms which 
is indicated by a reduction in dendritic branching and a decrease in neurogenesis par-
ticularly in the hippocampus and, to some extent, in the frontal cortex (38, 39). Such 
changes, together with an activation of the pro-inflammatory cytokines by chronic stress 
and depression, also enhance apoptosis through their indirect excitotoxic and metabolic 
actions (40). Thus stress induced hypercortisolaemia and pro-inflammatory cytokines 
share a final common pathway that leads to impaired neuronal plasticity and deficits in 
central neurotransmission. 
 The possible link between hypercortisolaemia and depression is further provided by 
the changes induced by antidepressants and glucocorticoid receptor antagonists such as 
mifepristone (41). Thus preliminary clinical evidence has shown that the sensitisation of 
the central glucocorticoid receptors by such treatments, that results in the re-
establishment of the feedback inhibition of cortisol release, are correlated with the 
attenuation of the symptoms of depression (42). 
Is there a link between depression and dementia: the clinical 
perspective 
There is overwhelming evidence that inflammatory changes are an important causative 
factor in the pathology of Alzheimer’s disease and related dementias (43). The increase 
in beta amyloid (Aβ) is not only a major pathological feature of such dementias but is 
also responsible for stimulating inflammatory responses in the brain. These changes 
include an increased expression of cell adhesion molecules, pro-inflammatory cytokines 
and the activation of microglia in the brain parenchyma (44). In vitro studies have also 
demonstrated that Aβ induces IL1β and IFNγ from vascular cells thereby inducing a 
cascade of inflammatory changes (45, 46). In addition, the infiltration of macrophages 
together with CD4+ and CD8+ T-cells, from the periphery have been detected in Aβ 
deposits in cerebral vessels in patients with cerebral amyloid angiopathy (47). 
 The combination of Aβ and pro-inflammatory cytokines is linked to the increase in 
apoptosis in the brains of patients with dementia (48). For example, there is evidence 
that lymphocytes show a significant increase in DNA fragmentation in Alzheimer 
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patients when compared to aged, but normal, controls (49). This change has been linked 
to an increase in the intracellular concentration of calcium ions, a prerequisite for 
apoptosis (50) that has not been recorded in lymphocytes from aged control subjects. 
Furthermore, apoptotic cell death is preceded by the expression of apoptosis-associated 
molecules such as p53, Fas (CD95/APO-1) and IL1β converting enzyme. Whereas the 
normal brain is partly immunologically privileged, in patients with inflammatory 
diseases such as multiple sclerosis, stroke, Alzheimer’s disease and possibly major 
depression, Fas is widely expressed in the brain (51). This apoptotic protein is expressed 
on CD4+ and CD8+ T-cells and on NK cells. Such observations provide a further link 
between the inflammatory changes in the brain and increased apoptosis that preludes 
dementia. 
 Despite these convincing observations regarding the inflammatory changes in 
patients with Alzheimer’s disease, it is somewhat surprising to find that IL6 , a major 
pro-inflammatory cytokine that is elevated in the plasma and CSF of patients with major 
depression, has been reported to be unchanged (52) or even decreased (53, 54) in the 
blood of Alzheimer’s patients. Some investigators have, however, reported that IL6 is 
increased in these patients (55). Some of these differences may be accounted for by the 
methods used to assay IL6. Thus the concentration of IL6 in the serum and CSF is often 
at the limit of detection while in in-vitro studies, in which stimulated lymphocytes are 
isolated by gradient centrifugation, the cells are stressed which may alter their pheno-
type. 
 It has also been argued that the decrease in pro-inflammatory cytokines in Alz-
heimer’s disease is a consequence of the hypercortisolaemia (53) although this does not 
explain why cytokines such as IL6 remain elevated in depressed patients where hyper-
cortisolaemia also commonly occurs. 
 The cognitive changes and dysphoria that are common symptoms in the early stages 
of Alzheimer’s disease have been correlated with the increase in pro-inflammatory 
cytokines such as IFNα (6). Despite the equivocal evidence regarding the rise in plasma 
IL6 concentration in Alzheimer patients, there are reports that the IL6 concentration 
correlates with the severity of dementia (56).From the numerous studies of the changes 
in the immune system of patients with dementias, it would appear that the inflammatory 
changes can trigger an increased synthesis and accumulation of Aβ (57). The accumula-
tion of Aβ then initiates a further cascade of inflammatory changes in the brain involv-
ing pro-inflammatory cytokines and neurotoxic free radicals such as ‘nitric oxide (NO) 
(58); this involves the activation of the NFkbeta pathway and the complement system. 
Neuronal COX 2 expression is also increased in Alzheimer’s disease and the resulting 
increase in PGE2 contributes to the subsequent deterioration in the clinical state of the 
patient (59). In addition, the rise in IL1β may also indirectly contribute to the cognitive 
deficit by inhibiting cholinergic function (60); a deficit in acetylcholine is generally 
accepted as the primary neurotransmitter that is causally involved in the cognitive and 
memory deficits in the dementias (42). 
 The question arises whether the increase in Aβ is a reflection of the rise in pro-
inflammatory cytokines, an important consideration if major depression predisposes to 
dementia. In support of this connection, there is evidence that severe head trauma in 
young persons can result in a large number of amyloid plaques shortly after the trau-
matic event (61). The accumulation of Aβ was shown to occur secondarily to the stress 
induced activation of the microglia that precipitate the release of IL1; the Aβ formed 
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then stimulated the “cytokine cascade”, a key element in the pathogenesis of dementia 
(62). 
 Further evidence in support of the hypothesis linking the outcome of chronic 
depression with dementia, comes from studies on the progression of an HIV infection to 
AIDS. It is well known that severe life-stress, and bereavement of a partner with AIDS, 
is associated with a rapid progression of HIV to AIDS and a consequent increase in 
mortality (63). For example, it has been reported that changes in immune function, such 
as a reduction in NK cells correlates with the incidence of depression and the progres-
sive deterioration in the clinical status of the patients with HIV/AIDS (10, 64, 65) 
although not all investigators have found such an association (66). Nevertheless, such 
studies do provide possible support for the hypothesis that impaired immune function 
associated with the symptoms of depression may act not only in the progression of an 
AIDS infection but also to the onset of AIDS dementia in those patients that do not die 
as a consequence of secondary infections or cancer. 
Changes in pro-inflammatory cytokines in depression and dementia 
Evidence implicating a role for the pro-inflammatory cytokines in the aetiology of 
depression has been provided by studies on the changes in IL1, IL6 and TNFα in 
depressed patients and also by the effects of IFNα on psychiatrically normal individuals 
being treated for hepatitis or a malignancy. Such studies have implicated these cyto-
kines as causative factors in the symptoms of major depression.  
 These symptoms include depressed mood, anxiety, cognitive impairment, lack of 
motivation, loss of libido, sleep disturbance and deficits in short-term memory. Such 
symptoms usually disappear once the plasma cytokine concentrations return to normal 
(67). These changes appear to be a consequence of the neurotransmitter and endocrine 
changes induced by the cytokines rather than the pathological condition for which the 
treatment has been administered (67-69). It is perhaps not surprising therefore to find 
that the symptoms of depression frequently occur in patients recovering from a chronic 
infection, those with multiple sclerosis (70), allergies (71) and rheumatoid arthritis (72). 
In all these situations, pro-inflammatory cytokines are known to be over-expressed (73). 
The initial studies linking depression with an abnormality of the immune system (74), 
impaired mitogen stimulated lymphocyte proliferation (75) and reduced NK cell activity 
(76) in untreated depressed patients, changes that largely returned to normal once the 
patient recovered from the depressive episode.  
 Recent research into the immune changes occurring in depression has concentrated 
on cytokines, soluble cytokine receptors and plasma acute phase proteins. For example, 
positive acute phase proteins have been shown to increase while the negative acute 
phase proteins decreased in depression, changes that are known to be a consequence of 
the action of IL6 on liver function (77). In addition, complement proteins (C3,C4 ) and 
immunoglobulin M are increased in depressed patients. Such changes are evidence of 
immune activation involving both the inflammatory cytokines and B-cells that are 
activated by the pro-inflammatory cytokines. Further evidence of immune activation in 
depressed patients is provided by the studies showing that the plasma concentration of 
IL1, IL6, IFNγ, soluble IL6 and IL2 receptors, and the IL1 receptor antagonist, are 
raised. These changes are correlated with a rise in plasma acute phase proteins (78). 
Effective antidepressant treatments largely attenuated such immune changes. In addition 
to the increases in pro-inflammatory cytokines, there is also evidence of an increased 
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number of T-helper, T-memory, activated T-cells and B-cells that act as a source of the 
plasma cytokines (79-81).  
 From these changes, it would appear that in depression there is an imbalance 
between the inflammatory and the anti-inflammatory arms of the immune system, the 
cytokines from the T1 pathway (such as IFNγ) becoming predominant over those of the 
anti-inflammatory T2 (for example, IL4) pathway. A recent study has shown that the T3 
cytokine, transforming growth factor β1 (TGFβ1) whose function is to re-establish the 
balance between the T1 and T2 pathways, is increased in depressed patients following 
effective antidepressant treatment (82). Though TGFβ1 is reported as a regulatory 
cytokine that keeps the balance between Th1 and Th2 cytokines (83), precisely how the 
increases in the pro-inflammatory cytokines are attenuated by TGFβ1 in depressed 
patients is unclear.  
The role of the microglia in inflammatory changes in the brain 
Localised inflammatory responses in the brain parenchyma have been associated with 
the pathogenesis of a number of neurological disorders including Alzheimer’s disease 
and Parkinson’s disease (84, 85). At these lesion sites, activated microglia release such 
inflammatory mediators as TNFα and PGE2 (86).It is well-known that PGE2 is an 
important mediator of inflammation. In vitro evidence shows that PGE2 secretion from 
lymphocytes of depressed patients is increased (87), as is the PGE2 content of the saliva, 
serum and CSF of such patients (88, 89). Of the pro-inflammatory cytokines,IL6 ap-
pears to play a key role in the synthesis of this prostaglandin both in vitro and in vivo 
(89, 90).  
 Conversely, different types of antidepressants have been shown to inhibit the 
secretion of pro-inflammatory cytokines and to reduce the synthesis of PGE2 (91-93). 
This raises the interesting possibility that the reduction in pro-inflammatory cytokines 
and inflammatory mediators such as PGE2 in the brain may be associated with the 
therapeutic actions of antidepressants (94). As it appears that the pro-inflammatory 
cytokines increase the inducible form of cyclo-oxygenase (COX2) in the brain, it would 
be expected that COX2 inhibitors would not only attenuate the central inflammatory 
changes but also exert an antidepressant effect. There is some clinical evidence to 
support this view. Thus rofecoxib, when administered to a large group of patients 
suffering from osteoarthritis, was found to reduce the symptoms of those who were 
suffering from co-morbid depression; 15% of the patients had depression at the start of 
the study which decreased to 3% at the end of the period of treatment (95). Other 
clinical studies have suggested that the COX2 inhibitor celecoxib has positive effects on 
cognitive function in depressed patients (95). It should be noted that celecoxib has also 
been shown to have beneficial effects as an “add-on” component to resperidone in the 
treatment of schizophrenia (96, 97).  
 There are several mechanisms that are postulated to be involved in the aetiology of 
depression. It is commonly assumed that a decrease in both the noradrenergic and 
serotonergic functions are causally related to the changes in the mood, motivation and 
cognitive changes associated with the disorder, There is now experimental evidence to 
show that the inhibition of COX 2 is associated with a rise in the synthesis of serotonin 
in the cortex of the rat brain (98). In addition, PGE2 has been shown to reduce the 
release of noradrenaline from central noradrenergic neurons, an effect that would be 
blocked by the COX2 inhibitors. Thus inhibition of COX2 activity in the brain contrib-
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utes not only to the reduction in inflammatory changes but also to an enhancement of 
biogenic amine function. PGE2 is probably one of the most potent inflammatory media-
tors in terms of the initiation and propagation of inflammation within the brain (99). 
Both clinical (89, 100) and experimental studies have shown that there is an increase in 
the tissue concentrations of PGE2 in depression and in an animal model of depression 
(87). In the brain, the microglia act as macrophages. On activation, they release pro-
inflammatory cytokines, PGE2 and neurotoxic metabolites of the kynurenine pathway 
(101). Recent experimental evidence has shown that lipopolysaccharide (LPS), an 
activator of macrophage activity and a cause of brain inflammation, induces mitochon-
drial PGE2 synthase and cyclo-oxygenase-2 (COX2) activity in activated microglia 
thereby increasing the synthesis of PGE2 at sites of inflammation in the brain (102). 
This provides a possible mechanism to explain the inflammatory changes in patients 
with depression or dementia, changes that contribute to neurodegeneration. Nitric oxide 
(NO) can also act as an inflammatory mediator that contributes to neurodegeneration 
(103) and is raised in the plasma of depressed patients (104). NO is produced by both 
the constitutive and inducible forms of NO synthase that are associated with neurons 
and microglia (105-107). Recent evidence suggests that pro-inflammatory cytokines 
activate inducible NOS thereby increasing NO; apoptosis results from the nitrosylation 
of DNA (108). The increase in peripheral and central macrophage activity associated 
with the inflammatory changes initiate, via the activated microglia, increases in PGE2 
and NO that further potentiate the inflammatory changes (figure 2). 
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Figure 2—Relationship between the main neurodegenerative pathwaysin the brain and depression. (+) 
Pathways that are increased in depression, and probably dementia. IDO, indoleamine 2,3-dioxygenase; iNOS, 
inducible nitric oxide synthase; CRF, corticotrophin releasing factor; COX2, inducible cyclo-oxygenase 2; 
PGE, prostaglandin E; HPA, hypothalamic pituitary adrenal; NO, nitrous oxide; IL, interlaukin; NOS, nitrous 
oxide synthase; BDNF, brain derived neurotrophic factor. 
 
 Thus in both depression and dementia, PGE2, NO and neurotoxic metabolites from 
kynurenine pathway appear to play an important role central inflammatory processes 
that contribute to neurodegeneration. 
Neurodegeneration and the role of neurotoxic metabolites of the 
tryptophan pathway 
The depletion of tryptophan from the diet results in a reduction in serotonin in the brain 
that correlates with the onset of a depressed mood state (109). Tryptophan is metabo-
lised by two main pathways, by tryptophan hydroxylase leading to the synthesis of 
serotonin in the brain and by indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-
dioxygnase (TDO) resulting in the formation of kynurenine (110, 111). It has been 
hypothesized that, in depression the metabolism of tryptophan by IDO and TDO is 
increased thereby reducing the availability of the amino acid to synthesise serotonin 
(101). TDO is located in the liver and the brain while IDO is found in the lungs, pla-
centa, blood and brain (112, 113). The activity of TDO is increased by tryptophan and 
by cortisol. As hypercortisolaemia frequently occurs in both depression and dementia, it 
would be anticipated that TDO is overactive in patients with these disorders. By contrast, 
IDO activity is increased by pro-inflammatory cytokines such as IL6 and IFNγ and 
inhibited by anti-inflammatory cytokines such as IL4 (114, 115). Thus the activities of 
both TDO and IDO are likely to be increased in depression and dementia as a conse-
quence of the rise in circulating cortisol and the pro-inflammatory cytokines. There are 
two main stages in the metabolism of tryptophan following the actions of the dioxy-
genases (116). Following the conversion of tryptophan to kynurenine by IDO or TDO, 
kynurenine is metabolised by kynurenine hydroxylase to the neurotoxic metabolites 3-
hydroxykynurenine, 3-hydroxy- anthranilic acid and quinolinic acid. An alternative 
pathway involves the conversion of kynurenine to 3-hydroxyanthranilic acid by 
kynureninase. These form the neurodegenerative arm of the tryptophan-kynurenine 
pathway. 
 Alternatively, kynurenine may be metabolised by kynurenine aminotransferase to 
the neuroprotective end product kynurenic acid (117). The mechanisms whereby quino-
linic and kynurenic acids act as neurotoxic and neuroprotective agents respectively is 
related to their activation or inhibition of the N-methyl-D-aspartate (NMDA) receptor, 
quinolinic acid and 3-hydroxyanthranilic acids being agonists of the NMDA receptor 
while kynurenic acid is an antagonist (118, 119). It has also been hypothesized that the 
imbalance between those NMDA receptor antagonist and agonist pathophysiology of 
chronic or treatment resistant depression (101).  
 In the brain, the metabolism of tryptophan by the enzymes of the kynurenine 
pathway occurs in both astrocytes and microglia (120, 121) the former producing 
mainly kynurenic acid while the latter produces the neurotoxic end products 3-hydroxy-
kynurenine, 3-hydroxyanthranilic acid and quinolinic acid (122). Astrocytes have been 
shown to metabolise quinolinic acid and thereby reduce the neurotoxic impact that may 
arise following microglia activation. From the foregoing evidence, it can be hypothe-
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sised that inflammatory changes in both depression and dementia involve the activation 
of microglia and an increase in the inflammatory challenge to the brain. Such changes 
also occur in patients with hepatitis who have been treated with the pro-inflammatory 
cytokine IFNα and who developed depressive symptoms as a side-effect of the treat-
ment. In these patients, it has been shown that the plasma kynurenic acid concentration 
was reduced thereby suggesting that the neurodegenerative metabolites were increased 
(123). More recently we have shown that similar changes occur in the blood of patients 
with major depression (124). The result of this study also showed that therapeutically 
effective antidepressant treatment increased the neuroprotective kynurenic acid in the 
blood in those patients suffering from an acute episode of depression but not in those 
with chronic depression. These changes occurred irrespective of the clinical improve-
ment in the symptoms of the patients. This suggests that the progress to dementia may 
increase as the depression becomes more chronic. 
 In patients with major depression, shrinkage of the hippocampus (125, 126), a 
decrease in the number of astrocytes and a neuronal loss from the pre-frontal cortex (38, 
127, 128) and the striatum (129) have been reported. Such findings support the view 
that neurodegenerative changes occur in several discrete regions of the brain in patients 
suffering from chronic depression. Furthermore, as the astrocytes are a major source of 
kynurenic acid, apoptosis of these cells would result in a reduction in the neuroprotec-
tive effect of kynurenic acid. There is evidence that in the astrocytes the kynurenine 
pathway is limited due to the absence of kynurenine hydroxylase. As a consequence, 
astrocytes only produce a very low concentration of the neurotoxin quinolinic acid and a 
relatively high concentration of the neuroprotective agent kynurenic acid (111). Fur-
thermore, in astrocytes IDO is preferentially induced by IFNγ, a cytokine that also 
induces the catabolism of quinolinic acid (111). However, it is also apparent that the 
increase in the synthesis of kynurenine by the astrocytes can indirectly contribute to the 
formation of quinolinic acid by the microglia.  This situation would be compounded by 
the increased activation of the microglia by the pro-inflammatory cytokines with the 
consequent rise in the concentration of the inflammatory mediators PGE2 and NO. 
Figure 3 summarises the pathways involved in the metabolism of tryptophan by the 
kynurenine pathway and the relationship with inflammatory cytokines in depression. 
 The inhibition of neuronal repair mechanisms resulting from the reduction in 
neurotrophic factors that follow the rise in blood and tissue cortisol (130), apoptosis of 
astrocytes which are the sources of several neurotrophic factors (131), and the possible 
disruption of the phospholipase D pathway that has anti-apoptotic properties and is 
involved in neurite formation and repair (132), further contribute to the neuronal loss. 
Another association between depression and dementia is through this IDO initiated 
kynurenine pathway related neurotoxicity. An immunohistochemical study has proven 
that the immunoreactivity of IDO and quinolinic acid are high in the hippocampus of 
Alzheimer’s disease patients (133). 
 So far, emphasis has been placed on the role of inflammatory mediators and neuro-
toxins produced by the kynurenine pathway on the possible causes of the neurodegener- 
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Figure 3—Outline of the kynurenine pathway and its induction by proinflammatory cytokines, that results in 
the accumulation of major neurotoxic metabolite. IL, interleukin; TGF, transforming growth factor; IFN, 
interferon; IDO, indoleamine 2,3-dioxygenase; HPA, hypothalamic pituitary adrenal. 
 
ative changes in the brain that eventually develops into dementia. Recently, experimen-
tal evidence has shown that transgenic mice that over-express human tau protein (a 
prominent feature of different types of dementia) show depressive-like behaviour in the 
Forced Swim Test. This test is widely used to predict antidepressant activity and is 
based on the observation that when rodents are placed in a container of warm water 
from which they cannot escape, they soon adopt an immobile posture. This is assumed 
to reflect a state of “learned helplessness” that reflects a depressive-like state (134). This 
behavioural state was reversed by the administration of the selective serotonin re-uptake 
inhibitor antidepressant fluvoxamine. In vivo microdialysis studies showed that the 
release of serotonin from the pre-frontal cortex was reduced in the transgenic mice, an 
effect that was reversed by the fluvoxamine treatment. The results of this study suggest 
that transgenic mice over-expressing human tau protein show symptoms of depressive-
like behaviour that are associated with a reduction in serotonergic function. As the 
behavioural and neurotransmitter changes are reversed by a SSRI antidepressant, it 
would appear that serotonin may provide a link between the pathological effects of tau 
protein and the subsequent depressive-like state. It would be incautious to extrapolate 
from  this sub-chronic  study in a  transgenic  mouse to the  complex clinical situation in        
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Figure 4—Theoretical pathway linking chronic depression to dementia. PGE2, prostaglandin E2; IDO, 
indoleamine 2,3-dioxygenase; KYN, kynurenine; KA, kynurenic acid; QA, quinolinic acid. 
which multiple pathological changes contribute to the onset of dementia. Nevertheless, 
the experimental studies do provide evidence in support of the hypothesis that the long-
term outcome of chronic depression is often dementia. Further evidence for this hy-
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pothesis comes from the study by Steffens et al (4) who demonstrated a link between 
late-onset depression and the rise in plasma apolipoprotein E4 which is widely consid-
ered to be a risk factor for late-onset Alzheimer’s disease. Figure 4 summarises the 
possible pathways leading from depression to dementia. 
Conclusion 
Neuronal loss is a common feature of major depression and dementia. The progress of 
major depression to dementia could result from the chronic inflammatory changes that 
are linked to the activation of the microglia. The activation of inducible COX2 and NOS 
by the pro-inflammatory cytokines further increases the inflammatory challenge to the 
brain. As there is evidence that the kynurenine pathway is also activated by pro-
inflammatory cytokines, it seems likely that the concentrations of the neurotoxins 3-
hydroxykynurenine, 3-hydroxyanthranillic acids and quinolinic acid will also increase 
as a result of the activation of the microglia. The increased apoptosis of the astrocytes, 
with a reduction in the availability of the neuroprotective agent kynurenic acid, further 
adds to the impact of the neurodegenerative changes. Hypercortisolaemia, a common 
feature of both dementia and major depression, and apoptosis of astrocytes decreases 
the synthesis of neurotrophic factors thereby reducing neuronal repair. This process may 
be further enhanced by the disruption of the phospholipase D pathway that normally 
plays an important role in neurite formation and neuronal repair. This hypothesis may 
assist in explaining the degenerative changes in the hippocampus and other brain re-
gions that are the features of chronic major depression. It may also explain why chronic 
depression is frequently a prelude to dementia in the elderly patient. 
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Immune changes in major depression: cause or coexistence or 
consequence? 
A meta-analysis of over 180 studies, in which more than 40 immune parameters were 
determined, concluded that there is substantial evidence for a link between a dysfunc-
tional immune system and depression (1). Both psychological stress and depression can 
induce immune dysfunction. In addition, the HPA and HPT axes are known to be 
involved in the immune changes induced by stress (2). Depressed patients frequently 
exhibit hypercortisolaemia associated with an elevation of CRF (3), the key neuropep-
tide that is involved in the integration of the immune, endocrine and neurotransmitter 
systems in response to stress. Thus CRF has been shown to alter both innate and cellular 
immunity and antibody formation (4, 5). Such effects also involve the activation of the 
sympathetic nervous system, an event that has been shown to suppress both natural 
killer cell (NKC) activity and T-lymphocytes (6, 7). 
 One of the earliest immune changes that relate to depression concern an increase in 
the number of white blood cells, specifically involving a change in the proportion of 
neutrophils and lymphocytes and a reduction in NKC’s (8-17). It is of interest to note 
that the changes in the proportion of NKC’s depend on the gender of the depressed 
patient. Thus the reduction in the NKC’s is greater in male than in female patients (18) 
although it must be emphasised that this finding is controversial (19). 
 In regard to the cytokine changes in depression, several studies have reported that 
there is an increase in pro-inflammatory Th1 cytokines in patients with major depres-
sion (20-22) but not all studies can confirm this (23, 24). In some studies, the increase in 
pro-inflammatory cytokines has been linked to suicide attempts (25) rather than with 
major depression as such (26). Furthermore, differences in the changes in pro-
inflammatory cytokines have been reported in melancholic verses non-melancholic 
depression (27) and between dysthymia and major depression (28). The variability in 
results may reflect the differences in study design, for example, whether drug naïve or 
medicated patients are studied, the sub-types of depression included and whether basal 
or stimulated cytokine concentrations are measured. Nevertheless, despite these limita-
tions, it would appear that there is reasonable evidence to support the view that pro-
inflammatory cytokines are increased in major depression. 
 In the present studies, the balance between representative Th1, Th2 and Th3 cyto-
kines were determined in plasma before and following antidepressant treatment. The 
results clearly demonstrate that there is an increase in Th1 cytokines and a decrease in 
Th2 cytokines; Th3 cytokines increase in patients that recover from depression. It was 
of interest to find that the female patients showed an increase in Th1 cytokines follow-
ing effective treatment whereas male patients, and post-menopausal patients, showed a 
reduction in the Th1 cytokines following antidepressant treatment. Other studies have 
shown somewhat similar changes (29-31). However, it is still uncertain whether the 
immune changes are the cause or the effect of depression. If the cytokine changes are 
related to the psychopathology of depression, as proposed by the neurodegeneration 
hypothesis, then the cytokine changes would be expected to be reflected in changes in 
the brain. To investigate this possibility, the effects of IFN alpha were studied in rats. 
 IFN has been shown to induce depressive-like states in patients being treated for 
certain malignancies and hepatitis B and C (32-34); IFN also induces depressive-like 
behaviour in rats (35). The results of study of the effects of IFN on the behaviour and on 
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changes in microglia and astrocytes (36) clearly demonstrate that this cytokine induces 
an increase in the pro-inflammatory cytokines in the hypothalamus and hippocampus 
that are associated with depressive-like behaviour. These changes are reversed by 
chronic paroxetine treatment. IFN was also shown to reduce the density of astrocytes in 
the dendate gyrus and CA3 region of the hippocampus; chronic fluoxetine treatment 
failed to prevent such changes (37). Other investigators have shown that, in rats, stress 
can cause a reduction in astrocyte number and in astrocyte volume; events that are also 
not reversed by antidepressant treatment (38). 
 Taken together, these results suggest that the imbalance between Th1,Th2 and Th3 
cytokines in the peripheral blood of depressed patients might contribute to the structural 
and functional changes induced by IFN treatment and that are also associated with 
major depression. Antidepressants may reduce the inflammatory changes but would 
appear to be much less effective in reversing the changes in the astrocytes that are 
associated with inflammation. As the astrocytes play an important role in neuroprotec-
tion it seems probable that such irreversible changes could be a prelude to neurodegen-
eration. This clearly requires further investigation. 
 To further confirm that immune changes can be the causative factor in pathophysi-
ology of major depression, an experimental study was undertaken in which olfactory 
bulbectomised (OBX) rats were treated with the cyclooxygenase (COX) 2 inhibitor 
celecoxib. If the immune or inflammatory changes are causal factors, when those 
changes are reversed by inhibition of inflammatory cascade, the behavioural and central 
cytokine changes should also be reversed. It was shown that OBX rats treated with 
celecoxib did not show central pro-inflammatory cytokine changes or the behavioural 
changes that occurred in the untreated OBX rats. This lends further support to the 
hypothesis that inflammatory changes in the brain are important contributing factors to 
the behavioural abnormalities associated with the behaviour of the OBX rats. 
 The recent study on changes in tryptophan and kynurenine pathway metabolites in 
patients with major depression (39) demonstrated indirectly that impaired neuroprotec-
tion occurred in depressed patients. An imbalance in the neuroprotection-
neurodegeneration kynurenine pathway was indicated by low plasma neuroprotective 
metabolite, kynurenic acid in depressed patients compared to their healthy controls. 
Moreover, antidepressant treatment did not reverse this impairment in neuroprotection 
in those patients with repeated episodes of depression despite the improvement in the 
clinical symptoms. This finding supports the hypothesis that explains how the cytokine 
imbalance is related to tryptophan and kynurenine metabolism and how that could lead 
to impaired neuroprotection in chronic major depression. However, to validate this 
further, it is necessary to measure the neurotoxic metabolites, such as 3-
hydroxykynurenine and quinolinic acid, to obtain direct evidence of imbalance neuro-
protection-degeneration in terms of kynurenine pathway metabolites. Since there is 
epidemiological evidence to indicate the relationship between depression and dementia, 
the metabolic changes that lead to impaired neuroprotection in combination with other 
associated central inflammatory changes also require evaluation in order to verify the 
pathophysiological link between depression and dementia. 
 In conclusion, it would appear that immune changes in depression are both cause 
and consequence of depressive disorders. The immune changes induced by physical or 
psychological stress may trigger depressive illness and the depressive illness may 
induce further immune changes and impaired neuroprotection in the brain. This vicious 
cycle (figure 1) may explain the role of immune changes in depression. 
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Figure 1—Stress-immune changes-depression interaction 
Future perspectives 
Though our studies support to a considerable extent the proposed hypothesis, it is still 
necessary to prove the certain critical points such as impaired neuronal network and 
evidence of neurodegeneration in major depression through systematic morphological 
or imaging studies. Moreover, it is necessary to investigate whether low kynurenic acid 
concentrations in plasma persist by performing long-term follow-up studies. The effects 
of different types of antidepressant and non-pharmacological treatments and changes in 
the kynurenine pathway in other types of psychiatric disorder and in the dementias also 
need to be explored. In addition, as the kynurenine pathway is widely distributed in the 
body, the reduction in kynurenic acid may be influenced by many different biological 
factors such as genetic, environmental or gene-environment interactions. These factors 
also require further investigation. Lastly, detailed experimental studies leading to a 
possible diagnostic tool, or a novel antidepressant treatment, by manipulating the 
neuroprotection-neurodegeneration balance in the kynurenine pathway are also neces-
sary to extend the scope of the present studies. 
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Summary 
Depression is a psychiatric disorder in which all neurotransmitters, endocrine and 
immune systems are involved. Moreover, these changes can lead to structural changes 
in the brain. There are different antidepressants developed since mid 20th Century and 
those improved the clinical symptoms though there are still deficiencies. Recently, 
immune system changes become of interest in pathophysiology of depression and 
development of new antidepressant. This thesis addressed the role of neuro-immune 
balance in clinical and experimental depression, and the role of certain current antide-
pressants and immunomodulation in this context. 
 
Chapter 1.1, the general discussion is the introduction in which the scientific back-
ground in brief related to the reason why the hypothesis was formulated. 
 
Chapter 1.2 is the hypothesis formulated upon which this whole thesis was based and 
the research studies were designed and carried out. This hypothesis explained the 
integrated role of neuro-immune-endocrine-metabolism interaction in pathophysiology 
of depression and the possible coping mechanisms. 
 
Chapter 2 addressed the importance of the balance between representative Th1, Th2 and 
Th3 cytokines in drug naïve or drug free depressed patients and the effect of antidepres-
sant treatment. The results clearly demonstrate that there is an increase in Th1 cytokines 
 
Chapter 3 addressed the issue that the proinflammatory cytokine IFNα induced depres-
sive-like behaviour in rats and both peripheral and central cytokine changes. The central 
cytokine changes occurred in the area like hypothalamus and hippocampus, which are 
involved in depression. Moreover this chapter addressed the preventive role of SSRI 
paroxetine in IFNα-induced depression. 
 
Chapter 4 addressed the observation that the proinflammatory cytokine, IFNα, induced 
not only the cytokine changes in the brain, but also reduction in astrocyte density in 
hippocampus area of the brain in the rats. In addition, this chapter explained that the 
SSRI antidepressant, fluoxetine could not fully prevent the changes. As the astrocytes 
play an important role in neuroprotection it seems probable that such irreversible 
changes could be a prelude to neurodegeneration. 
 
Chapter 5 addressed the fact that immunomodulation could improve the symptoms of 
depression through an experimental study undertaken in olfactory bulbectomised (OBX) 
rats which were treated with the cyclooxygenase (COX) 2 inhibitor celecoxib. It was 
shown that OBX rats treated with celecoxib did not show central pro-inflammatory 
cytokine changes or the behavioural changes that occurred in the untreated OBX rats. 
 
Chapter 6 addressed the changes in tryptophan and kynurenine pathway metabolites in 
patients with major depression which demonstrated indirectly that impaired neuropro-
tection occurred in depressed patients. An imbalance in the neuroprotection-
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that recovered from depression. 
and a decrease in Th2 cytokines in depressed and Th3 cytokine increases in patients
 SUMMARY 
neurodegeneration kynurenine pathway was indicated by low plasma neuroprotective 
metabolite, kynurenic acid in depressed patients compared to their healthy controls. 
Moreover, antidepressant treatment did not reverse this impairment in neuroprotection 
in those patients with repeated episodes of depression despite the improvement in the 
clinical symptoms. This finding supports the hypothesis that explains how the cytokine 
imbalance is related to tryptophan and kynurenine metabolism and how that could lead 
to impaired neuroprotection in chronic major depression. 
 
In the chapter 7 reviewed the possible relationship between depression and dementia 
through the metabolic changes that lead to impaired neuroprotection in combination 
with other associated central inflammatory changes also require evaluation in order to 
verify the pathophysiological link between depression and dementia. 
 
The last chapter, Chapter 8 discussed on the overall finding through the work in this 
thesis and the future perspectives. 
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A wish from a scientist 
A scientist in a laboratory, 
An animal experiment for a study. 
The arenas, squares and objects, 
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Time comes to take blood and brain, 
Make a wish in my heart, with great pain, 
In the expense of these little creatures, 
I could help the sufferings in near future. 
 
© Aye Mu Myint, 2006, International Library of Poetry 
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